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ABSTRACT
In many criminal investigations, valuable information regarding the physical
appearance of suspected perpetrators or the time and order of events that transpired are
provided by eyewitness accounts. However, the information obtained from eyewitnesses
is often constrained by human recollection or subjective accounts and provides a biased
description of the perpetrator’s appearance or an inaccurate time line of events.
Additionally, in numerous situations eyewitness accounts may not be available. An
increasing reliance therefore is placed on the biological evidence recovered during
criminal investigations to act as a silent witness, providing unbiased and scientific
information that may aid in the resolution of criminal investigations. While the current
capabilities of operational forensic crime laboratories include analytical methods to allow
for a determination of the origin of a biological stain and for the recovery of a genetic
profile of the donor, the sensitivity of such methods is not always sufficient to
accommodate the limited amounts of biological material often recovered in forensic
casework, Therefore, it is critical that continual advancements in the analysis of low
template samples be made. In this report, we have sought to identify novel protein, RNA
and DNA biomarkers that, in combination with enhanced profiling strategies, would
allow for a determination of the time since deposition, the body fluid of origin and the
genetic profile of the donor (“genetic eyewitness”) of forensic low template specimens.
First, we have developed a novel strategy for the determination of the time since
deposition of dried bloodstains using spectrophotometric analysis of hemoglobin. An
examination of the Soret band (λmax = 414nm) in aged bloodstains has revealed a
iii

previously unidentified hypsochromic shift as the age of the stain increases. The extent of
this shift permits a distinction to be made between stains that differ in age by only
minutes, hours, days and months thus providing the highest resolution of any previously
developed method. We also demonstrate that it may be possible to utilize a decline in
enzyme activity to determine the age of a forensic biological stain. Second, we
demonstrate that the differential expression of a panel of nine miRNAs allows for the
identification of the body fluid origin of forensic biological stains using as little as 50pg
of total RNA. This is the highest reported sensitivity of any RNA-based approach and
this assay has demonstrated a high degree of specificity for each body fluid tested. The
final task of this work was to identify novel DNA biomarkers and to develop enhanced
profiling strategies to allow for greater sensitivity and reliability in the genetic profiling
of low template samples. We demonstrate that the use of laser capture micro-dissection
and enhanced amplification strategies resulted in the ability to obtain genetic profiles
from as few as 2-5 epithelial cells and 5-10 sperm cells with greater reproducibility than
previously reported studies. The use of a novel whole genome amplification method
provided the ability to not only increase the quantity of genetic material obtained from
micro-dissected cells but also the ability to recover additional genetic information from
individual samples using novel DNA biomarkers.
The novel biomarkers and profiling strategies described in this report provide the
basis for the establishment of a molecular “genetic eyewitness” from low template
forensic samples and demonstrate the future potential for routine and reliable analysis of
trace amounts of genetic material recovered from low template biological evidence.
iv
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CHAPTER ONE: INTRODUCTION

In many criminal investigations, valuable information regarding the physical
appearance of suspected perpetrators or the time and order of events that transpired are
provided by eyewitness accounts. However, the information obtained from eyewitnesses
is often constrained by human recollection or subjective accounts and provides a biased
description of the perpetrator’s appearance or an inaccurate time line of events.
Additionally, in numerous situations eyewitness accounts may not be available. An
increasing reliance therefore is placed on the biological evidence recovered during
criminal investigations to act as a silent witness, providing unbiased and scientific
information that may aid in the resolution of criminal investigations. While the current
capabilities of operational forensic crime laboratories include analytical methods to allow
for a determination of the origin of a biological stain and for the recovery of a genetic
profile of the donor, the sensitivity of such methods is not always sufficient to
accommodate the limited amounts of biological material, or low template samples, often
recovered in forensic casework.
Low template samples are those containing less than 100pg of template DNA,
which is equivalent to approximately 15 diploid or 30 haploid cells. Low template sample
analysis (typically referring only to the recovery of DNA profiles) is often not possible
due to the sensitivity limits of the analytical techniques currently used by operational
crime laboratories. The frequency of occurrence of low template samples in forensic
casework therefore necessitates continual advancements in the strategies used to analyze
1

such samples. However, these advancements should not only be limited to the recovery
of genetic profiles, but should include improved methodologies to recover other probative
information from these samples as well. The aim of this work was to identify novel
macromolecular biomarkers and to develop enhanced profiling strategies to establish a
molecular “genetic eyewitness” from low template forensic samples. This “genetic
eyewitness” ideally would be able to provide a determination of the time since deposition
of biological stains, an identification of the body fluid of origin of biological stains, and
an identification of the donor’s genetic profile with greater reliability and discrimination.
The determination of the time since deposition of biological stains remains an
unsolved problem in forensic casework. Currently, no reliable and accurate methods to
determine the age of a stain have been developed for standard samples and certainly not
for low template samples. Early TSD methods for bloodstains focused on the molecular
changes to hemoglobin that occur over time such as oxidation and degradation of the
protein chains [1-5]. One example of such a method reported the use of HPLC
chromatography to measure the of α-chain:heme ratio in ageing stains [2]. With this
method, a linear decrease in the α-chain area/heme area was observed, on a logarithmic
scale, as stain age increased. In a subsequent study, a peak designated as “X” was
detected only in aged stains, and the area of this peak increased as the age of the stain
increased [3]. Various other studies have utilized HPLC analysis of hemoglobin to
determine the age of bloodstains [1,5]. While these studies demonstrated a crude linear
relationship between the age of a stain and the degradation of hemoglobin, the reported
methods possess limited resolution for TSD estimates. Several previous methods have
2

been proposed that utilize changes in the characteristic α and β bands (~540 and 576nm
respectively) of the visible spectral profile of hemoglobin or involve an assessment of
potential mRNA degradation products in

aged

bloodstains.

However,

these

methodologies have failed to gain widespread acceptance due to poor analytical
sensitivity (large sample consumption) and inadequate resolution between different stain
ages (often requiring years difference in age). Two recent studies involving attempts to
determine approximate age of biological stains have examined RNA degradation, using
both mRNA and rRNA [6,7]. The first utilized semi-quantitative duplex and competitive
RT-PCR methods to estimate the approximate age of bloodstains based on the
assumption that degradation to mRNA occurs from the 5’end and that the degradation of
two housekeeping genes is different over time [7]. However, the authors did not adduce
any evidence that mRNA in biological stains degrades in this manner and, in any case,
the resolution afforded by these methods was too low (5 years) to be of forensic use [7].
The other RNA study examined ratios of β-actin mRNA and 18S rRNA as a function of
time using real-time PCR and demonstrated a linear relationship over time [6]. However,
this study produced low-resolution time estimates (approximately 30 days) and did not
take into account differing environmental conditions [6]. Based on the results of these
studies, it is evident that novel strategies are needed in order to obtain higher-resolution
and accurate time-since-deposition determinations. Therefore, the first aim of this work
was to determine if novel protein biomarkers could be identified to allow for a
determination of the time since deposition of low template forensic biological evidence.

3

Another aspect of the analysis of forensic biological evidence that needs
improvement in order to be able to accommodate low template samples is body fluid
identification. In the past, standard practice in forensic casework analysis typically
included a preliminary screening of evidentiary items recovered during the investigation
of criminal offenses in order to identify the presence, and possible tissue origin, of
biological material. The presence of biological material such as blood, semen and saliva
stains can indicate the location of potential sources of DNA that, once recovered, could
be used to identify the donor of the biological material. Typically, conventional methods
for body fluid stain analysis are carried out in a serial manner, with a portion of the stain
being tested for only one body fluid at a time. Frequently multiple tests are required to
first presumptively identify the presence of biological fluids followed by additional
testing in order to confirm the presence of the fluid or identify the species of origin.
Therefore these methods are costly not only in the time and labor required for their
completion, but also in terms of the amount of sample consumed during the performance
of each assay. While these conventional methods can confirm the presence of human
blood and semen, none of the routinely used serological and immunological tests can
definitely identify the presence of human saliva or vaginal secretions. With the large
volume of cases that operational crime laboratories are faced with processing every year,
a significant amount of the total time spent on an individual case can be devoted solely to
the screening of evidentiary items for the presence of biological materials. The inability
to positively confirm the presence of certain biological fluids, the consumption of
valuable samples and the time and labor required has resulted in a trend to bypass
4

conventional body fluid identification methods and proceed straight to the analysis of
DNA present in forensic samples. After all, it is argued, the recovery of human DNA
from evidentiary items would directly indicate the presence of human biological material
and thereby eliminate the need for conventional body fluid testing.
There are several disadvantages to bypassing the body fluid identification step
during bio-molecular forensic analysis. First, the analytical methods used to analyze
DNA are considerably more expensive that basic serological testing. Therefore the use of
DNA analysis as a means to identify the presence of human biological material may not
be justifiable from a budgetary standpoint. Additionally, a smaller number of samplings
from an individual piece of evidence may be collected in an attempt to reduce the
associated cost of analysis. Critical evidence may be missed using this type of approach
that might have been identified using a larger preliminary screen with basic serological
methods. A second disadvantage of the disuse of body fluid identification methods is that
often the identification of the biological material present is crucial to the investigation
and prosecution of the case. For example, consider a sexual assault of a child with a step
father suspect where the step-father’s DNA profile was recovered from samples taken
from the child’s underwear and bedding. The step-father could argue that the source of
the DNA was from his skin cells deposited from casual and frequent contact with the
child’s clothing and bedding. However, the finding that his DNA originated from a
semen stain and not skin cells would be more problematic for him to explain away and
would more strongly support the allegation of a sexual assault. Another example of a
case demonstrating the importance of identifying the body fluid could be that DNA from
5

a sexual assault victim is found in a suspect’s vehicle and the suspect claims it was
present due to casual contact since the victim had ridden in his car numerous times.
However, the significance of this evidence would increase if the source of the DNA could
be shown instead to originate from the victim’s vaginal secretions, a circumstance which
would be more difficult to attribute to casual contact as opposed to a sexual assault. A
final example of the importance of determining the body fluid of origin involves the
presence of blood in a sexual assault case. If blood is present in the vaginal canal, it needs
to be proven that the blood is venous blood resulting from trauma rather than menstrual
blood originating from a victim’s regular menstrual cycle. In this instance, it is necessary
to make a distinction between menstrual blood and venous blood which cannot be
accomplished using conventional methods.
The routine use of body fluid identification methods prior to DNA analysis awaits
the development of suitable molecular genetics based methods that are fully compatible
with the current DNA analysis pipeline. In order for any new body fluid assay to be
suitable for forensic casework it must demonstrate a high degree of specificity for each
body fluid, permit parallel analysis of the different biological fluids, be completed in a
timely and labor efficient manner and must be sufficiently sensitive. Messenger RNA
(mRNA) profiling of tissue specific gene transcripts with forensic samples for the
identification of body fluids has recently been reported and appears to satisfy most of
these criteria [8-10].
The mRNA in aged and compromised dried appears to be sufficiently stable for
forensic analysis [11]. However, as with DNA, heat and humidity is detrimental to RNA
6

stability and results in a time dependent fragmentation of the polynucleotide chain [11].
Typically forensic assays employ some biomarkers whose amplicon sizes are > 250 bases
which results in amplification failure when highly degraded samples are encountered
[12]. Thus reduced size amplicons for STR and mitochondrial DNA profiling methods
are being increasingly used for the analysis of degraded samples [13-22]. Similarly
smaller amplicons could be designed for use in mRNA based forensic assays although
they may present additional technical assay design challenges because of the need to
ensure that contaminating genomic DNA does not confound the analyses. In theory,
another way to reduce the amplicon size would be to employ short RNA biomarkers in
stead of mRNA. Recently, there has been an explosion on interest in a class of small
non-coding RNAs, microRNAs, whose regulatory functions in various developmental
and biological processes have been identified [23-40]. The role of miRNAs in various
cancers and diseases are also being evaluated [41-52]. Several studies have examined the
relative abundance of miRNAs in human tissue with numerous miRNAs reported to be
tissue-specific [53-63]. However, as yet no studies have described miRNA expression in
forensically-relevant, dried biological fluids (blood, semen, saliva, vaginal secretions and
menstrual blood). In theory, it should be possible to identify miRNAs that, due to their
differential tissue expression, could be used to identify the body fluid origin of forensic
biological stains with a high degree of sensitivity and specificity and thus ideally suited
for low template samples. Therefore, the second aim was to determine if miRNA
expression assays could be used to determine the body fluid source of forensic low
template samples.
7

The determination of the genetic profile of the donor of low template or low copy
number (LCN) samples is a current challenge facing operational crime laboratories.
Currently, no methods that allow for sufficient reproducibility and ease of interpretation
are available for use in forensic casework. Since only a small number of cells are present
in LCN samples, recovery of genetic profiles is difficult using standard STR methods and
often results in total failure or recovery of a partial profile. Hence LCN methods have
been developed (based upon increasing the PCR cycle number (ICN) to increase allelic
signal intensity) to permit profile recovery from limited quantity samples. Interpretation
of the data obtained from these LCN analyzed samples requires novel considerations [6466]. The occurrence of allelic drop-out or drop-in is significantly higher in LCN samples
due to stochastic effects, and can result in false homozygous classifications and in false
heterozygous classifications, respectively. Additionally, LCN samples exhibit significant
peak height imbalance and are more susceptible to interference from contamination. The
frequency of LCN samples in forensic casework warrants development of additional
methodologies to ICN that allow for more successful recovery of genetic information.
While it has been demonstrated that single cells can be isolated from certain tissue
samples with micro-dissection techniques, the ability to consistently recover a DNA
profile from single cells has not been demonstrated [67-74]. Most work done with single
cells has involved the use of tumor cells, and the analysis of these cells is limited has
normally been limited to one genetic marker. The success of recovery of genetic profiles
from these single cells is often not consistent. No studies have demonstrated the ability to

8

consistently recover full autosomal STR profiles from single cell samples, which is the
routine method of DNA analysis in forensic casework [68].
In an attempt to increase the recovery of DNA profiles from LCN samples, the
use of increased cycle number has been suggested, with the assumption that sufficient
amounts of the amplified product would be produced to allow for detection and analysis
[6]. However, this method may not always be efficient, with additional cycles at high
temperatures leading to a decrease in inefficiency of Taq DNA polymerase [75]. This
results in less amplified product being produced, unless the process is halted for fresh
enzyme to be added before the additional cycles. However, no studies have demonstrated
successful analysis of single cells using only increased cycle number. Another approach
to the analysis of LCN samples utilizes whole genome amplification (WGA) strategies,
including primer extension pre-amplification (PEP), degenerate oligonucleotide-primed
PCR (DOP) and multiple displacement amplification (MDA) [69,76-88]. These WGA
methods employ various random-sequence primers with typically low stringency
annealing conditions to amplify large tracts of the genome in an attempt to increase the
effective number of starting templates prior to any downstream analysis. By preamplifying the limited amount of genetic material in the sample, sufficient quantities of
template theoretically can be produced to overcome stochastic effects resulting from low
copy number templates. However, few studies have demonstrated the suitability of these
WGA methods for use with forensic casework samples [89-92]. The application of these
WGA methods to cells isolated using laser capture micro-dissection techniques has also
not been widely examined [93]. Therefore, it is evident that it may be possible to improve
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low template sample analysis with additional research efforts. As a result, the final task of
this work was to identify novel DNA biomarkers and to develop enhanced profiling
strategies to allow for greater sensitivity and reliability in the genetic profiling of low
template samples.
In summary, the overall aim of this work was to identify novel protein, RNA and
DNA biomarkers that, in combination with enhanced profiling strategies, would allow for
the development of a “genetic eyewitness” profiling system to provide investigators with
the who, what and when of forensic low template samples. The “when” or time since
deposition was accomplished through spectrophotometric analysis of hemoglobin.
Additionally, we demonstrate that it may be possible to utilize a decline in enzyme
activity to determine the age of a forensic biological stain. The “what” or identification of
the body fluid of origin was accomplished by the development of the miRNA profiling
assays using a panel of nine differentially expressed miRNAs. The “who” or
determination of the genetic profile of the donor of low template samples was achieved
using laser capture micro-dissection and enhanced amplification strategies. Collectively,
our findings constitute the basis for the establishment of a molecular “genetic
eyewitness” from low template forensic samples.
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CHAPTER TWO: RESEARCH DESIGN AND METHODOLOGY

Preparation of Body Fluid Stains

General
Body fluids were collected from volunteers using procedures approved by the
University of Central Florida’s Institutional Review Board. Informed written consent
was obtained from each donor. Blood samples were collected by venipuncture into
additive-free vacutainers and 50 μl aliquots were placed onto cotton cloth and dried at
room temperature. Blood samples from 12 non-primate animal species (dog, cat, horse,
crane, cow, sheep, coyote, tortoise, lamb, Patagonian cavy, ferret, deer) and 10 primate
species (spider monkey, rhesus macaque, pig-tailed macaque, brown lemur, chimpanzee,
baboon, howler monkey, cynomolgous monkey, African green monkey, and spot-nosed
guenon) were obtained from various sources: Tuscawilla Oaks Animal Hospital, Oviedo,
FL (dog, cat); HemoStat Laboratories, Dixen, CA (sheep, cow, horse); Central Florida
Zoo, Sanford, FL (brown lemur, howler monkey, spot-nosed guenon); Brevard Zoo,
Melbourne, FL (crane, coyote, tortoise, lamb, Patagonian cavy, spider monkey, rhesus
macaque, pig-tailed macaque); donation from laboratory members (coyote, deer); West
End Animal Hospital, Gainesville, FL (ferret). Liquid blood samples from African green
monkey, cynomolgus monkey, baboon and chimpanzee were obtained from
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Bioreclamation, Inc. (Westbury, NY). For all blood samples, fifty microliter aliquots
were placed on cotton cloth and dried overnight at room temperature.
Freshly ejaculated semen was provided in sealed plastic tubes and stored frozen
until they were dried onto sterile cotton swabs. Saliva samples were provided in sealed
plastic tubes and stored frozen until they were dried onto sterile cotton swabs. Buccal
samples were collected from donors using sterile swabs by swabbing the inside of the
donor’s mouth. Saliva samples from two cats and two dogs were collected by swabbing
the inside of the animal’s mouth using sterile cotton swabs. A primate saliva sample
(spot-nosed guenon) was obtained by donation from the Central Florida Zoo (Sanford,
FL). Semen-free vaginal secretions and menstrual blood were collected using sterile
cotton swabs.

Preparation of Bloodstains (Time Since Deposition)
Blood samples were collected by venipuncture into additive-free vacutainers and
50 μl aliquots were placed onto non-sterile cotton cloth The bloodstains were stored at
various temperatures (22oC, 30oC, 37oC) and humidity levels (50%, 75%, 80%, 85%,
90%) for varying lengths of time (15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 12-18
hours, 24 hours, 48 hours, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years). All
bloodstains were collected at the desired time intervals, placed in a sealed plastic bag and
stored at -47oC until needed. Experiments were conducted either in the laboratory (22oC,
50% humidity) protected from light, in incubators (specified temperatures, 50%
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humidity), or in a MicroClimate® Humidity Chamber MCH-3 (Cincinnati Sub-Zero,
Cincinnati, OH).

Environmental Samples (Time Since Deposition)
50 μl aliquots of human blood were dried onto non-sterile cotton cloth. The
samples were placed inside a glass tank to protect them from rain with a vented bottom to
allow for free air-flow into the tank. The samples were placed on a roof top to allow for
direct exposure to sunlight for various lengths of time including 15 minutes, 30 minutes,
1 hour, 3 hours, 6 hours, 18 hours, 24 hours, 48 hours, and 1 week. Upon collection, all
samples were placed into sealed plastic bags and stored at -47oC until needed.

Environmental Samples (miRNA)
50 μl aliquots of human blood, semen and saliva were dried onto cotton cloth.
Vaginal secretion samples were collected using sterile cotton swabs. These samples were
exposed to different environmental conditions including various temperatures and
environmental influences including humidity and rain. The environmental conditions
were as follows: (i) room temperature storage (22oC), (ii) 37oC storage, (iii) outside
covered (OC) – exposed to heat, light and humidity, and (iv) outside uncovered (OUC) –
exposed to heat, light, humidity and rain. Samples from all sets of conditions were
collected at varying lengths of time and the following samples were used in the present
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study: room temperature (1 year, 18 months-2 years), 37oC (3 months, 6 months), OC (3
days, 7 days, 1 month), and OUC (1 day, 3 days, and 7 days). Temperature ranges,
humidity levels, and amount of rain were recorded for the samples placed in outside
conditions.

Menstrual Cycle Samples (miRNA)
Two female individuals donated vaginal swabs over the course of a 28-day period.
Females at two different life stages participated in the study, one experiencing
menstruation at regular intervals and one in perimenopause. Participants were asked to
collect a single semen-free vaginal swab during each day of the study, with the first day
of collection starting on the first day of menstruation if applicable.

Multiple Source Samples (miRNA)
Five-donor pooled samples were used for the initial miRNA screening in
forensically relevant fluids. Total RNA from each individual sample was extracted and
quantitated as described above. Equal quantities of total RNA from each donor were
combined in order to produce a 1ng/μl pooled sample for blood, saliva, vaginal secretions
and menstrual blood, and a 5ng/ μl pooled sample for semen. A 1μl aliquot of each
pooled sample was used in the reverse transcription assay.

14

Admixed body fluid samples (blood-semen, blood-saliva, blood-vaginal
secretions, semen-saliva, semen-vaginal secretions and saliva-vaginal secretions) were
created by combining two different body fluid stains or swabs (50 μl stain for blood,
semen and saliva, or a single vaginal secretion swab) in the same tube. Total RNA was
extracted as described above.

Tissue Samples (miRNA)
Total RNA from 20 human tissues (adipose, bladder, brain, cervix, colon,
esophagus, heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small
intestine, spleen, testes, thymus, thyroid, and trachea) included in the FirstChoice®
Human Total RNA Survey Panel was obtained from Applied Biosystems/Ambion
(Austin, TX). All tissues included in the panel were 3-donor pooled samples and were
certified to contain small RNAs including miRNAs and snRNAs. Total RNA from
human skin was obtained from Biochain Institute, Inc (Hayward, CA).

Mock Casework Samples (miRNA)
Swabs of a beverage container lid (plastic coffee cup lid, water bottle) using a
sterile cotton swab were collected after being deposited by volunteers. Saliva from a male
donor was deposited onto the skin of a female donor. After the saliva was allowed to dry,
the skin was swabbed using a sterile cotton swab. Portions of the outer wrapping of used
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cigarette butts (collected from a male and female donor) were removed for extraction.
Total RNA was extracted as described above.
An adhesive bandage that was used to cover a small cut on a donor’s finger was
obtained. The cotton pad in the center of the bandage had a reddish-brown appearance.
The entire cotton pad was removed from the bandage for extraction. Total RNA was
extracted as described above.
A post-coital sample was obtained from a female volunteer who recovered the
sample 18 hours post-coitus. A swabbing of both the vaginal canal and the cervicovaginal
region was collected. The volunteer was instructed to take the cervicovaginal swab by
brushing the cervix multiple times for at least thirty seconds. To insure that residual
semen from prior encounters were not present, a pre-coital cervicovaginal swab was also
obtained before coitus commenced but after an abstinence period of seven days.

Laser Capture Micro-dissection Slide Preparation

Body fluid swabs were removed from storage at -47oC and allowed to sit at room
temperature for at least 15 minutes prior to preparation of the cell suspension. A 1.5mL
microcentrifuge tube was filled with 1X PBS and a Spin-Ease extract basket was added.
The body fluid swab was placed in the liquid within the basket and agitated in order to
collect the cells. The tubes were centrifuged for 5 min at 13,000rpm in order to pellet the
cells. The PBS was then removed using a plastic transfer pipet and approximately 500μl
of fresh PBS was added. The cell pellet was agitated until the pellet was disrupted until
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an even cell distribution was achieved. The cell suspension was then heat fixed onto a
clean glass slide (for use with the Arcturus PixCell II system) or onto a proprietary
membrane slide (for use with the Leica LMD system). The heat fixation involved
placement of the slides onto a heat plate (low heat setting) for approximately 3-5 minutes.

Cell staining

Christmas Tree Stain (Nuclear Fast Red/Picroindigocarmine)
The nuclear fast red solution was prepared by dissolving 2.5g of aluminum sulfate
in 100mL of warm water. Fifty milligrams of nuclear fast red was then added to the
solution. The solution was filtered into amber bottles. The picroindigocarmine solution
was prepared by dissolving 1g of indigocarmine in 300mL of picric acid. The solution
was dispensed into small amber bottles. For slides prepared using the Christmas Tree
stain, the entire sample area was covered with the nuclear fast red solution for 15
minutes. Excess stain was removed by gentle flooding with deionized water. The sample
area was then covered with the picroindigocarmine solution for 10 seconds. Excess stain
was removed by gentle flooding with room temperature absolute ethanol.
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Hematoxylin and Eosin (H&E)
The components for the Harris Hematoxylin/Eosin stain were obtained from a
commercial source (Sigma-Aldrich). For slides prepared using the H&E stain, the entire
sample area was covered with the Harris hematoxylin solution for 1.5 minutes. Excess
stain was removed by gentle flooding with deionized water. The sample area was then
covered with Eosin for 30 sec. Excess stain was removed by gentle flooding with
deionized water.

Leica LMD Slides
Upon completion of the staining procedures described above, slides prepared for
use with the Leica LMD system were then dried at room temperature and then placed in
slide storage boxes for storage at 4oC.

Arcturus PixCell II Slides
The presence of moisture on slides to be used with the Arcturus PixCell II system
would result in failure of the instrument to remove cells from the glass slide. Therefore
additional processing of these slides was required during the staining procedures describe
above in order to remove any moisture. After slide preparation but prior to staining, the
specimen slide was placed in a glass jar containing approximately 25mL of 75% ethanol
for 30 seconds. It was then transferred to a glass jar containing 25mL of deionized water
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for 30 seconds. The procedure for staining with the Christmas Tree stain or the H&E
stain was then performed as described above. The slide was then transferred to a glass jar
containing 25mL of deionized water. The slide was then transferred to glass jars
containing 25mL of ethanol (75%, 95%, and 100%) for 30 seconds each. The slide was
then transferred to a glass jar containing 25mL of xylene for 5 minutes (performed in a
fume hood). The slide was allowed to air dry at room temperature and was stored in a
dessicator at room temperature. Prior to use, if the slide had acquired any moisture the
dehydration steps were repeated.

Laser Capture Micro-dissection

Leica LMD System
0.2ml flat-capped PCR tubes were inserted into the four tube holder positions.
Ten microliters of lysis buffer were added to the cap of each tube. The tube holder was
placed in position underneath the stage. The specimen slide was placed face down in the
slide holder and placed on the instrument. The specimen was brought into focus and the
laser power and speed and specimen balance were adjusted. Epithelial cells were
collected using a 40x objective (400x magnification) using the following laser settings:
power – 33, speed – 8, specimen balance – 28. Sperm cells were collected using a 63x
objective (630x magnification) using the following laser settings: power – 30, speed – 8,
specimen balance – 25.
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Arcturus PixCell II System
The specimen slide was placed on the microscope stage and help in position by
the use of the small vacuum on the stage. The area of interest was brought into view
using a joystick. The laser power and pulse duration were adjusted to ensure optimal laser
settings. A CapSure® HS LCM cap (Molecular Devices, Sunnyvale, CA) was placed onto
of the specimen slide. The appropriate number of cells was collected onto the cap. Once
all cells were collected, the cap was lifted and placed onto a clean slide to ensure that the
cells had been lifted from the specimen slide. The cap was then inverted and placed into a
sample tray. An ExtracSureTM device (Molecular Devices) was placed over the cap and
lysis buffer was added. A 0.5mL thin walled reaction tube was placed over the
ExtracSureTM device. The entire sample tray was covered with a pre-heated heat block
and the sample tray then placed in an incubator for lysis.

Extraction

DNA – Organic Extraction
DNA was extracted using a standard phenol: chloroform method [94]. Stains or
swabs were cut into small pieces and placed into a Spin-Ease tube (Gibco-BRL, Grand
Island NY). The tubes were incubated overnight in a 56oC water bath using 400 μl DNA
Extraction Buffer (100mM NaCl, 10mM Tris-HCl, pH 8.0, 25mM EDTA, 0.5% SDS),
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0.1mg/mL Proteinase K, and 10% 0.39 M DTT (added to semen containing samples).
After the overnight incubation, swab or stain fabric was placed into a Spin-Ease basket,
the basket inserted back into the original tube, and the samples centrifuged at 14,000 rpm
for 5 minutes to remove the absorbed fluid from the swab material. A volume of
phenol/chloroform/isoamyl alcohol equal to the volume of the crude extract was added
and vigorously intermixed by shaking. The aqueous layer, containing the DNA, was
removed. Precipitation of the DNA was accomplished by the addition of cold absolute
ethanol (two and a half times the volume of the aqueous layer extract) and allowed to
progress overnight at –20oC. The DNA was pelleted by centrifugation, washed once
using 70% ethanol and re-solubilized with 100 μl of TE-4 (10 mM Tris-HCl, 0.1 mM
EDTA, pH 7.5) overnight at 56oC.

DNA - Direct Lysis
Direct lysis of micro-dissected cells was performed using a modified
commercially available lysis buffer (Quick Extract, Epicenter). The Quick Extract lysis
solution was prepared by adding 9μl of Quick Extract buffer and 1μl of 0.39M DTT
(final concentration 0.039M) per sample. The DTT was made fresh daily. 10μl of lysis
solution per sample was used for both the Leica and Arcturus systems. For Leica
samples, the 0.2ml PCR tubes were briefly centrifuged and the lysis performed in a
thermocycler. For Arcturus samples, the lysis was performed in an incubator. The Quick
Extract lysis protocol is as follows: 65oC for 6 minutes, 98oC for 2 minutes.
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RNA
Total RNA was extracted from blood, semen, saliva, vaginal secretions and
menstrual blood with guanidine isothiocyanate-phenol:chloroform and precipitated with
isopropanol [95]. Briefly, 500 μl of pre-heated (56oC for 10 minutes) denaturing solution
(4M guanidine isothiocyanate, 0.02M sodium citrate, 0.5% sarkosyl, 0.1M βmercaptoethanol) was added to a 1.5mL Safe Lock tube extraction tube (Eppendorf,
Westbury, NY) containing the stain or swab. The samples were incubated at 56oC for 30
minutes. The swab or stain pieces were then placed into a DNA IQTM spin basket
(Promega, Madison, WI), re-inserted back into the original extraction tube, and
centrifuged at 14,000 rpm (16,000 x g) for 5 minutes. After centrifugation, the basket
with swab/stain pieces was discarded. To each extract the following was added: 50 μl 2
M sodium acetate and 600 μl acid phenol:chloroform (5:1), pH 4.5 (Applied
Biosystems/Ambion). The samples were placed at 4oC for 30 minutes to separate the
layers and then centrifuged for 20 minutes at 14,000 rpm (16,000 x g). The RNAcontaining top aqueous layer was transferred to a new 1.5ml microcentrifuge tube, to
which 2 μl of GlycoBlueTM glycogen carrier (Applied Biosystems/Ambion) and 500 μl of
isopropanol were added. RNA was precipitated for 1 hour at -20oC. The extracts were
then centrifuged at 14,000 rpm (16,000 x g). The supernatant was removed and the pellet
was washed with 900 μl of 75% ethanol/25% DEPC-treated water. Following a
centrifugation for 10 minutes at 14,000 rpm (16,000 x g), the supernatant was removed
and the pellet dried using vacuum centrifugation (56oC) for 3 minutes. Twenty
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microliters of pre-heated (60oC for 5 minutes) RNAsecureTM solution (Applied
Biosystems/Ambion) was added to each sample followed by an incubation at 60oC for 10
minutes. Samples were used immediately or stored at -20oC until needed.

DNase I digestion

Six units of TURBOTM DNase I (2U/μl) (Applied Biosystems/Ambion, Inc.) and
2.2 μl of Turbo DNase I Buffer (10X) were added to each RNA extract and incubated at
37oC for 1 hour. The DNase was inactivated at 75oC for 10 minutes. The samples were
used immediately or stored at -20oC until needed. Alternatively, DNase digestion was
performed using the Turbo DNA-freeTM kit (Applied Biosystems/Ambion) according to
the manufacturer’s protocol.

Protein
Approximately half of a 60 μl bloodstain was placed in a 1.5mL microcentrifuge
tube with 750 μl of 0.2M Tris-HCl, pH 8.0. The samples were allowed to extract
overnight at room temperature (protected from light). After the overnight incubation, the
stain pieces were placed in a spin basket and the samples were centrifuged at 14,000 rpm
(16,000 x g) for 3 minutes. The stain pieces and basket were then discarded. All extracts
were stored at -20oC until needed.
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Quantitation

DNA
DNA extracts and whole genome amplification products were quantitated with the
Quantifiler® Human or Quantifiler® Y Human Male Real-Time PCR Quantitation Kits
(Applied Biosystems, Foster City, CA) according to manufacturer’s recommended
conditions.

RNA
RNA extracts were quantitated with Quant-iTTM RiboGreen® RNA Kit
(Invitrogen, Carlsbad, CA) as previously described [8]. Fluorescence was determined
using a SynergyTM 2 Multi-Mode microplate reader (BioTek Instruments, Inc., Winooski,
VT).

Protein
All bloodstain extracts were quantitated using the Quant-ItTM Protein Assay Kit
according to manufacturer’s recommended conditions. The quantitation was performed
using a Synergy 2 Microplate Reader (BioTek, Winooski, VT). All samples were run in
duplicate and an average of the two measurements obtained.
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cDNA Synthesis

For the reverse transcriptase (RT) reaction, the miScript Reverse Transcription
Kit (Qiagen, Valencia, CA) was used according to manufacturer’s protocols. One
nanogram of total RNA from blood, semen, vaginal secretions and menstrual blood
extracts and 5 ng of total RNA from semen extracts were used in the RT reactions. A
reverse transcription negative reaction (containing total RNA and reaction buffer but no
reverse transcriptase enzyme mix) was performed for each sample.

Polymerase chain reaction

Autosomal STR Amplification
DNA extracts were amplified with commercially available STR amplification kits
including AmpFlSTR® Profiler Plus®, COFiler®, MinifilerTM and Identifiler® (Applied
Biosystems). Amplifications were either performed using standard conditions according
to manufacturer’s instructions (with the exception of Profiler Plus® and COFiler® where a
decreased reaction volume to 25 μl and 2X Taq Gold polymerase was used) or using
increased cycle number (from 28 cycles to 32 or 36) and an alternative polymerase
(Expand High Fidelity Polymerase, Roche Applied Science, Indianapolis, IN).
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Y Chromosome STR Amplification
DNA Extracts were amplified with a commercially available Y-STR
amplification kit (Yfiler® PCR Amplification kit, Applied Biosystems) or using multiplex
systems developed in our laboratory as previously described [96-100].

Whole Genome Amplification
The modified improved primer extension pre-amplification method was used to
pre-amplify DNA extracts and cell lysates as previously described [90].

Post-PCR Purification
Purification using the Qiagen MinElute columns was performed according to
manufacturer’s instructions. Ten microliters of product was eluted from the columns and
the entire 10 μl was used for capillary electrophoresis.

Capillary Electrophoresis

PCR products were detected using the ABI Prism 310 capillary electrophoresis
system.

A 1.75 μl aliquot of each amplified sample was added to 24 μl Hi-DiTM

formamide (Applied Biosystems) and 1 μl of GeneScanTM 500 ROXTM or 500
GeneScanTM 500 LIZTM internal lane standard (Applied Biosystems). Tubes were heated
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at 95°C for 3 min and snap cooled on ice for 2 min. Samples were injected through the
capillary using the module GS STR POP4 (1ml)F (5s injection, 15 kV, 60°C, run time 28
min, filter set F) or module GS STR POP4 (1ml)G5 (5s injection, 15 kV, 60oC, run time
28 min, filter set G5). An allelic ladder for each amplification kit was run with the
samples to allow for genotyping. Samples were subject to laser induced fluorescence, and
analyzed with GeneScan 3.1.2 Software.
Alternatively, PCR products were detected using the ABI Prism 3130 capillary
electrophoresis system. A 0.75 μl aliquot of each amplified sample was added to 9.7 μl
Hi-DiTM formamide (Applied Biosystems) and 0.3 μl of GeneScanTM 500 ROXTM or
GeneScanTM 500 LIZTM internal lane standard (Applied Biosystems). The 96-well plates
were heated at 95°C for 3 min and snap cooled on ice for 2 min. Samples were injected
through the capillary using the FragmentAnalysis36_POP7_1 module (16s injection, 15
kV, 60°C, run time 20 min, filter set G5 or F). An allelic ladder for each amplification
kit was run with the samples to allow for genotyping. Samples were subject to laser
induced fluorescence, and analyzed with GeneMapper 3.2 Software.

Real-Time (Quantitative) Polymerase Chain Reaction

Real-time PCR was performed using the Relative Quantitation protocol on an
ABI Prism 7000 Sequence Detection System (Applied Biosystems). One microliter of the
1 ng RT-reaction (blood, saliva, vaginal secretions, menstrual blood) and two microliters
of the 5 ng RT-reaction (semen) were amplified using the miScript SYBR® Green PCR
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kit and a 10x miScript primer assay (Human miScript Primer Assay Set v1.0, Qiagen)
according to manufacturer’s protocols, with minor modifications. A reduced reaction
volume of 25 μl was used as well as an increased number of amplification cycles (from
35-40 to 50 cycles). Additional snRNA (U6b) and snoRNA (U26, U27, U28, U29, U30,
U31, U38B, U43, U44, U48 and U90) primer assays for normalization studies were
obtained from Qiagen.

UV-Visible Spectroscopy

Microplate Reader
UV-Visible spectral profiles were obtained using a Synergy 2 Microplate Reader.
Spectral data was collected from 200-700nm in 1nm increments. Samples were run in a
clear, flat-bottomed 96-well reaction plate using 7.5 μg of total protein and brought to a
final reaction volume of 75 μl per well using 0.2M Tris-HCl, pH 8.0. All spectral data
was blank corrected using 75 μl of 0.2M Tris-HCl. All data was run in triplicate and an
average of the data was used in subsequent analysis.

Standard Bench-Top Spectrophotometer
UV-Visible spectral profiles were also obtained using a U-0080D Photodiode
Array Spectrophotometer (Hitachi, Pleasanton, CA). Spectral data was collected from
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200-700nm in 1 nm increments using a 5 μl cell (7.5 μg total protein used for analysis).
All spectral data was blank corrected using 5 μl of 0.2M Tris-HCl. All data was run in
triplicate and an average of the data was used in subsequent analysis.

Portable “Point-of-Use” Spectrophotometer
UV-Visible

spectral

profiles

were

also

obtained

using

the

portable

NanoPhotomerTM (Implen, Inc., c/o LABREPCO, Horsman, PA). Spectral data was
collected from 350-600nm in 1 nm increments. A 1μl aliquot of the bloodstain extracts
was added directly to the spectrophotometer for analysis. All data was run in triplicate
and an average of the data was used in subsequent analysis.

Enzyme Activity Assays (MTT-PMS colorimetric assays)

All assays were run on the Synergy 2 Microplate Reader using a kinetic
absorbance program: 3 minutes hold, absorbance read: 565mm for 30 minutes in 1
minute intervals. Each reaction was run in duplicate and the average maximum velocity
of each reaction was obtained. Two negative controls, including a no-substrate control
and a no-NAD/NADP control, were run with each assay in order to ensure that the
measured activity was resulting from the enzyme itself and not other non-specific
interaction between reaction components. All enzyme assays were performed in 200 μl
reactions using 3 μg of total protein, 7 mM MTT and 26 mM PMS. The reaction mixtures
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for each enzyme assay were prepared as follows: Lactate dehydrogenase – 16 mM
calcium lactate, 15 mM NAD in 0.05M Tris-HCl; Malate dehydrogenase – 100 mM Lmalic acid, 15 mM NAD in 0.1M Tris-HCl; Alcohol dehydrogenase – 60% Absolute
ethanol, 15 mM NAD in 0.05M Tris-HCl; Glycerate dehydrogenase – 160 mM DLGlyceric acid hemicalcium salt hydrate, 15 mM NAD in 0.1M Tris-HCl; 3hydroxybutyrate dehydrogenase – 150 mM (±) Sodium 3-hydroxybutyrate, 50 mM
MgCl2, 300 mM NaCl in 0.1M Tris-HCl; Glucose-6-phosphate dehydrogenase – 16 mM
D-Glucose 6-phosphate disodium salt hydrate , 25 mM MgCl2, 4 mM NADP in 0.2M
Tris-HCl; Phosphogluconate dehydrogenase – 24 mM 6-Phosphogluconic acid trisodium
salt, 30 mM MgCl2, 4 mM NADP in 0.5M Tris-HCl; Isocitrate dehydrogenase – 38 mM
DL-Isocitric acid trisodium salt, 30 mM MgCl2, 4 mM NADP in 0.5M Tris-HCl;
Phosphoglucomutase – 30 mM glucose-1-phosphate dipotassium salt hydrate, 2U
glucose-6-phosphate dehydrogenase, 30 mM MgCl2, 4 mM NADP in 0.05M Tris-HCl;
Gluconate dehydrogenase – 15 mM 6-phosphogluconic acid, 30 mM MgCl2, 4 mM
NADP in 0.2M Tris-HCl; L-xyulose reductase – 33 mM xylitol, 4 mM NADP in 0.5M
Tris-HCl. All reagents used in the enzyme assays were obtained from Sigma-Aldrich (St.
Louis, MO), except for NADP which was obtained from USB Corporation (Cleveland,
OH).
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CHAPTER THREE: RESULTS – TIME SINCE DEPOSITION

Spectral Analysis of Hemoglobin

Initial work to determine the time since deposition of forensic biological stains
involved an examination of dried bloodstains. The ultra-violet-visible (UV-VIS)
spectrum of hemoglobin was examined for any possible changes that could serve as
“molecular estimators” of the time since deposition. A characteristic spectral profile for
hemoglobin can be seen in Figure 1. A strong absorption peak, known as the Soret band,
can be observed at approximately 414 nm. Additionally, smaller absorption peaks
occurring at approximately 576 and 541 nm, known as the α and β peaks respectively,
can also be observed. It is the presence of these peaks that provide an indication of the
presence of blood. These peaks, as well as those found in the UV region of the
hemoglobin spectrum were examined for possible changes as the age of the bloodstain
increased.
Initial studies performed to examine changes in the spectral profiles of hemoglobin
involved a small number of room temperature bloodstains of different ages (15 minutes, 6
hours, 24 hours, 1 month, 3 months, 6 months and 1 year). These samples were selected
since there was a significant difference in their age and would hopefully provide an
indication of whether visible differences between bloodstains could be observed. Spectral
profiles from 200-450nm and 500-600nm were obtained because they contained the
characteristic hemoglobin absorption peaks and it was thought these areas might be of
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interest. An examination of the UV region (200-400 nm) of the hemoglobin spectral
profile did not result in the identification of any significant peaks of interest (Figure 2A).
However, several observations were made regarding the Soret band at ~414 nm (Figure
2A). A decrease in the Soret band absorption maximum was observed as the age of the
stain increases, as well as a possible shift in the wavelength where this band occurs
(Figure 2A). An examination of the remaining portion of the visible hemoglobin
spectrum, from 500-600nm including the characteristic β541nm and α576nm absorption
peaks, was also observed in these samples (Figure 2B). As can be seen from these
spectral profiles, deterioration of the α576nm and β541nm peaks can be observed in stains as
early as 1 month of age, with a progressive decline of these peaks as the age of the stain
increases. The peaks are completely unidentifiable in stains one year in age (Figure 2B).
Additionally, it was thought that the rate of decline of the α576nm and β541nm peaks may
not occur at the same rate. The absorbance values for the α576nm and β541nm peaks appear
to be similar for the 15 minutes and 6 hour samples. However, a slight difference in the
absorbance maxima can be seen starting with the 24 hour sample. It was therefore
thought that a ratio of the α576nm and β541nm peak absorbance values may also demonstrate
a correlation with the time since deposition.
As a result of these initial findings, a set of spectral shift parameters were developed
in order to further examine possible correlations with the time since deposition (Figure
3). Five spectral parameters were identified and included: 1) change in the maximum
absorbance of the Soret band (ΔAbsSoret); 2) change in the wavelength of the λmax for the
Soret band (ΔλSoret); 3) change in the absorbance of the β541nm band relative to the
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minimum at 560nm (ΔAbsβ(541-560)); 4) change in the absorbance of the α576nm band
relative to the minimum at 560nm (ΔAbsα(576-560)); 5) the ratio of absorbance change of
the α576nm and β541nm bands (ΔAbsβ(541-560)/ ΔAbsα(576-560)).
Initially, an examination of the parameters involving changes in absorbance values
for the Soret band and the α576nm and β541nm bands was performed. Previous attempts in
classic literature to determine the time since deposition using spectroscopic methods
typically involved changes to the α576nm and β542nm bands. However, in our experiments
parameters 1, 3, 4 and 5 (ΔAbsSoret, ΔAbsβ(541-560), ΔAbsα(576-560), ΔAbsβ(541-560)/ ΔAbsα(576560))

did not provide a reliable correlation with the age of the stain. Figure 4 depicts the

relationship obtained between the age of the stain and the change in absorbance of the
β(541-560nm) band. As can be seen from this data, month differences in stain age were
required before a possible correlation could be developed. The resulting r2 values were
also < 0.78 with a large standard error for several samples. There was also a large
separation between the two individuals within each storage condition. Similar results
were also obtained with the α(576-560nm) peak was examined (Figure 5). The r2 values were
higher (> 0.80) than those obtained for the β(541-560nm) band. However, month differences
in stain age were still required. This resolution would not be sufficient for use in forensic
casework.
Previous studies had demonstrated a difference in the morphology of the α576nm and
β541nm bands as the age of the stain increased. Therefore, the final parameter utilizing a
change in absorbance that was examined was an evaluation of the ratio of the ΔAbs of the
α576nm and β541nm bands (Figure 6). When a ratio of the two ΔAbs values was used, a
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stronger correlation with the age of the stain was observed (r2 > 0.94, except for one data
set whose r2 = 0.87). However, month differences in stain age were still required and
there was still a significant variation between the two sample sets stored at 37oC (Figure
6).
As a result of the poor resolution of the spectral parameters involving absorbance
changes in the three characteristic hemoglobin bands (Soret, α576nm, β541nm), attempts
were made to further examine the possible λSoret shift that was observed during initial
testing. This parameter was of particular interest since, to the best of our knowledge, it
had not been reported in any previously published studies. The λSoret was graphed as a
function of stain age for bloodstains that had been stored at room temperature (22oC) and
37oC samples for 15 minutes to 1 year (Figure 7A). From this data, a strong correlation
between the age of the stain and the ΔλSoret was observed (r2 = 0.96 and 0.84 for the
22oC and 37oC samples, respectively). A larger and more pronounced decrease in the
λSoret was observed for the samples stored at 37oC indicating a possible effect of
temperature on the shift. With the range of samples examined, it was difficult to see the
relationship in the early time points. In order to further examine the early time points,
only the 15 minutes to 2 days samples were plotted (Figure 7B). When this smaller set of
samples was examined, a strong correlation between the wavelength shift and the age of
the stain was demonstrated (r2 values of 0.95 and 0.98 for 22oC and 37oC samples,
respectively). As a result of the significant correlation observed in the minutes to year
and minutes to day intervals, additional time intervals were examined to determine if this
method could be utilized to distinguish samples minutes, hours, days, weeks and months
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different in age. The r2 values for each of the time intervals (15 min - 2 days, 15 min - 1
week, 15 min – 1 month, and 15 min – 1 year) for both bloodstains stored at both 22oC
and 37oC are provided in Table 1. The r2 value for each time interval for both
temperatures (except for the 15 min – 1 year interval for the 37oC samples) was > 0.95.
The slightly lower r2 value for the 15 min – 1 year 37oC sample set could be a result of
exposure to such a high temperature (~98oF) for a long period of time. It is unlikely,
except for in extreme cases, that bloodstains would be exposed to this level of constant
temperature. However, it does indicate that TSD estimates may be more accurate for
younger stains at extreme temperatures. Overall, this data demonstrated the potential to
distinguish bloodstains differing in age by minutes, hours, days, weeks and months.

Instrumentation
All previous data had been obtained using the BioTek Synergy 2 microplate reader.
Before any further work was conducted, an evaluation of the same sets of bloodstains
was performed using the bench-top Hitachi U-0080D Spectrophotometer. This was
performed in order to ensure that the Soret band shift would still be observed on a
different instrument and that it was not the result of the microplate reader itself. Table 2
provides a comparison of the λSoret obtained for bloodstains stored at 22oC for 15
minutes – 1 year using both the microplate reader and the bench-top spectrophotometer
(Hitachi U-0080D). As can be seen from this data, the same hypsochromic shift in the
λSoret was observed using both instruments. There were differences in the obtained
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wavelength values between the two spectrophotometers, with the values for the bench-top
spectrophotometer typically 0.7-1.7 nm higher (average = 1.1nm) than what was
observed for the microplate reader (Table 2). The total wavelength shift between the 15
minute and 1 year samples was generally the same between the two instruments for both
data sets (Table 2). The 22oC data set when run on the bench-top spectrophotometer had a
slightly larger overall shift, 7.7nm, compared to the 5nm overall shift that was observed
when the same samples were run on the microplate reader (Table 2). However, the 1 year
data point on the spectrophotometer had a larger standard error and therefore likely
caused the larger shift that what was observed on the microplate reader.
When the ΔλSoret was plotted against the age of the stain, the r2 for the 22oC data
sets (15 minutes to 2 days) on both instruments was greater than 0.91 (Figure 8). The
same trend was observed in the data from both instruments, with the wavelengths from
the spectrophotometer slightly higher than the microplate reader which was indicated in
Table 2. From this data it was evident that the observed shift is a genuine occurrence in
aged stains and can be observed on different types of spectrophotometers. The data also
indicated a need to calibrate any spectrophotometer that would be used for TSD
measurements using this method. A series of standards would need to be run prior to any
unknown samples. Table 3 provides a summary of the r2 values obtained on both
instruments for the 22oC and 37oC using both a 15 minute – 2 day and a 15 minute – 1
year data set. For all data sets, the r2 values from the microplate reader were slightly
higher than those obtained from the spectrophotometer, although all r2 values were
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acceptable. As observed with previous data, the r2 value for the extended range (15
minutes – 1 year) 37oC sample set was < 0.9 using both instruments.
The results of these experiments demonstrate the reproducibility of the ΔλSoret
measurements was using different spectrophotometers. The microplate reader does offer
the advantage of being able to run replicates of the same sample at the same time, as well
as the ability to run more samples at one time (96-well plate vs. a single cuvette with the
spectrophotometer). It also allows for the use of a disposable 96-well plate whereas a
standard bench-top spectrophotometer would require the re-use of a cuvette which would
need to be cleaned in between samples.

Environmental Influences

Humidity

Initial experiments demonstrated that temperature may have an effect on the rate of or
extent of the Soret band shift. Therefore the affects of temperature and humidity on the
ΔλSoret were further examined. All sample sets used previously had been stored at room
temperature (22oC) or in a 37oC incubator. The average humidity and temperature for the
laboratory (measurements taken in the mornings) were approximately 22oC and 50%
humidity. However, small changes throughout the day may have occurred. In order to
more accurately control the temperature and humidity to which the samples were
exposed, a Cincinnati Sub-Zero MicroClimate® Humidity Chamber MCH-3 was used
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(Figure 9). This chamber allowed for a range of temperatures from -65oC to 190oC and a
range of humidity from 10% to 95% to be used. The chamber is digitally controlled and
monitored. Samples were placed inside the chamber and were thus exposed to constant
temperatures and humidity levels.
Prior to performing the experiments, national temperature and humidity level
averages were examined in order to determine if ranges could be selected that would be
appropriate for most regions of the country (Figure 10). Most of the country experiences
humidity levels between 56% and 85% for most of the year with western states
experiencing lower humidity levels (35-50%) for most of the year (Figure 10A).
Therefore some states, such as Arizona or New Mexico, humidity levels above 60%
might not be that relevant. Additionally, humidity levels below 65% might not be that
relevant for states such as Florida which maintains humidity levels of 65% or higher
through the year. There appeared to be distinctive regions of average daily temperatures
throughout the country as well, with large variation within specific months through the
year (Figure 10B). This data indicated that different regions of the country will be
affected by differing humidity and temperatures and might therefore need to conduct
simple experiments using temperatures and humidity levels relevant to their particular
region and relevant to different times of the year in order to establish reference data for
their geographical region. As a result of this data, a range of humidity levels from 5090% (50, 75, 80, 85 and 90%) were selected for use with two different temperatures,
22oC and 30oC.

38

The affects of humidity on the ΔλSoret measurements for bloodstains stored at 22oC
can be seen in Figure 11A. As the humidity level increases, the hypsochromic shift is
reduced (lower r2 value) and is essentially not observed with 90% humidity (Figure 11A).
As a result of the differences observed between different humidity levels, in order to
determine the age of an unknown stain the storage conditions to which the sample was
exposed would need to be known (or estimated.) The affects of 50, 75, 80 and 85%
humidity on samples stored at 30oC can be seen in Figure 11B. Again, as the humidity
level increases, the hypsochromic shift is reduced (lower r2 value).
It is evident from the graphs provided in Figure 11 that the affects of humidity are
different depending on what temperature the sample is exposed to. For example, for
bloodstains stored at 22oC, there is a progressive reduction in the hypsochromic shift as
the humidity level increases (Figure 11). It was expected that the same trend would be
observed for the bloodstains stored at 37oC. However, it can be seen that the extent of the
hypsochromic shift with 50% and 75% humidity is quite similar (Figure 11). Therefore it
is possible that at higher temperatures the affect of humidity is lessened and a higher
humidity level is needed to cause a reduction in the hypsochromic shift.

Temperature

The previous experiments had examined the affects of different humidity levels at a
constant temperature. An indication of the additional affect of temperature was also
obtained. Therefore to further examine the affects of temperature, samples were placed at
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a constant humidity (50%) at various temperatures, including -20oC, 4oC, 22oC (one set at
room temperature lab storage and one set stored in the humidity chamber), 30oC and
37oC. The λSoret was plotted for each temperature as a function of stain age (Figure 12).
The hypsochromic shift was more significant and occurred at a faster rate with increased
temperature (Figure 12). This data again indicated the need to have some knowledge or
reasonable estimate of the environmental conditions that any unknown bloodstain sample
was subjected to prior to collection and analysis.
Of additional interest was the -20oC sample set. As can be seen from Figure 12,
almost no change in the λSoret was observed. This data suggested that bloodstains
removed from a crime scene and brought back to the laboratory for future analysis could
be stored at -20oC without any further change to the λSoret. In order to further
demonstrate the ability to store bloodstains at -20oC without affecting ΔλSoret
measurements, three data sets were prepared: 1) samples extracted immediately upon
collection, 2) samples collected and stored at -20oC for two to three weeks, and 3)
“original” storage consisting of a mixture of samples stored at -47oC (15 minutes through
24 hours) prior to analysis and samples tested immediately (2 days, 1 week). The results
of the various storage conditions can be seen in Figure 13. Similar ΔλSoret plots were
obtained for bloodstains stored at each of the conditions described above. Therefore, it
would be possible for bloodstains to be collected at a crime scene and stored frozen (20oC) until ready for analysis without any significant alteration of the ΔλSoret values.
This would be of vital importance to crime laboratories where evidence is often not
examined immediately upon arrival at the laboratory.
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Outside Storage

The previous experiments examined the affects of storage at constant
temperatures and humidity levels. However, many criminal offenses will not occur
indoors in a controlled environment with relatively stable temperatures and humidity
levels. Often crime scenes are located outside with samples exposed to fluctuating
temperatures and humidity levels, sunlight, moisture, bacterial growth, and possible smog
or other air pollutants. Therefore, it was necessary to examine bloodstains that were
stored outside. Bloodstains were placed outside and covered (OSC), exposed to direct
sunlight but protected from rain and collected at various times through a one week period
(15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 18 hours, 24 hours, 48 hours and 1
week). During this week period the samples were exposed to a reported average
temperature of 27.1oC (low – 22.7oC, high – 35.7oC) and an average humidity of 81.1%
(low - 46%, high – 97.9%). Previous experiments had involved samples stored at 22oC,
30oC and 37oC. It was therefore assumed that the graph of the ΔλSoret for the OSC
samples would be observed in between the graphs for the 22oC and 37oC samples.
The ΔλSoret of the OSC samples was graphed along with the 22oC data sets
(50%, 75%, 80%, 85%, 90% humidity). As anticipated, the hypsochromic shift for the
OSC sample set was greater and occurred at a faster rate compared to all of the 22oC data
sets (Figure 14A). Even though the average temperature that the OSC samples were
exposed to was 27.1oC, it was thought that the ΔλSoret could still be slightly greater than
that of the 30oC sample set as a result of the exposure of the OSC samples to an average
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high of 35.7oC. As can be seen in Figure 14B, the ΔλSoret for the OSC samples was
greater than the 30oC sample sets (50%, 75%, 80% and 85% humidity). Additionally, the
ΔλSoret for the OSC samples was also greater than that of the 37oC data set (Figure 15).
While the average high temperature for the OSC data set was 35.7oC, there were three
days where the recorded high temperature was greater than 37oC (38.1oC – 39.4oC) which
could have accelerated the ΔλSoret in the OSC samples. Additionally, since the
bloodstains were exposed to direct sunlight at various times during the day, it is possible
that they experienced temperature much higher than the reported temperatures which are
often recorded in shaded areas. Without a direct and continuous measurement of the
actual temperature, the reported average temperature and humidity levels can only be
used as a crude approximation of the actual temperatures. It is also possible that sunlight
or smog and other air pollutants could also contribute to an increase in the ΔλSoret of
samples exposed to outside environmental conditions. Additional work will need to be
conducted to further examine the environmental influences affecting the ΔλSoret for
samples stored outside as it appears that environmental conditions could significantly
confound TSD determinations.

Non-Probative Samples – Car Trunk

In an attempt to further examine the affects of heat and humidity using samples
more akin to casework samples, bloodstains were stored inside the trunk of a car for
various lengths of time ranging from 25 minutes to 1 week, including 25 minutes, 1 hour,
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3 hours, 18 hours, 24 hours, 48 hours, 5 days (112 hours), and 1 week (Figure 16A). A
small digital thermometer with humidity gauge was placed inside the car trunk to allow
for continuous monitoring of temperature and humidity. During the week period, the
bloodstains were exposed to an average temperature of 44.2oC (high – 44.6oC, low –
43.4oC) and an average humidity of 49% (high – 60%, low – 40%). Due to the extreme
temperature, a more significant hypsochromic shift compared to previous data sets was
expected. The ΔλSoret was determined in comparison to the OSC samples and the 37oC
samples since the highest temperatures were observed with these sample sets (Figure
16B). As can be seen from Figure 16B, the car trunk data was located in between the
OSC and 37oC sample exhibiting a greater than 7 nm hypsochromic shift. It is also
evident from this data that the OSC samples, as previously discussed, likely experienced
temperatures much higher than the reported daily temperatures. From the data shown in
Figure 16B, it is predicted that the OSC bloodstains would have experienced
temperatures greater than 44oC (112oF) as evidenced by the greater hypsochromic shift.

Molecular Basis for the Hypsochromic shift
Before further experiments were conducted, a molecular basis for the
hypsochromic shift needed to be developed that could explain the observed affects of
humidity and temperature. The precise mechanism for the observed shift is unknown but
a possible mechanism can be posited. As the age of the stain increases, protein
conformational changes (loss of secondary structure, disruption of hydrogen bonding,
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etc) may occur. The previously protected heme cavity may become more exposed as a
result of these structural changes. Water, if allowed entry into the cavity, will
successfully compete with the His residue (from Hb) coordinated to Fe(II) in the 6th hexacoordinate position. The presence of the more electronegative oxygen will then cause the
Fe(II) electrons to change from a low spin (paired) state to a high spin (unpaired) state.
This causes Fe(II) to be more susceptible to oxidation. Over time, Fe(II) would then be
oxidized to Fe(III). As a result of this oxidation, the electron configuration for the Fe
molecule will therefore be altered and can interact with the π bonds of the porphyrin ring
structure of hemoglobin. This interaction may cause an increase in energy of π to π*
transitions thereby resulting in absorbance at a shorter wavelength or a hypsochromic
shift.
It is more difficult to explain the effects of temperature and humidity on the extent
of the hypsochromic shift. With regard to temperature it’s well characterized effect on
chemical reaction rates (such as the oxidation of Fe(II) Æ Fe (III)) may explain a greater
shift with increasing temperature. With humidity, one might have expected that the
higher humidity would result in more retained water and the bigger the hypsochromic
shift.

However the converse is found in that higher humidity results in less of a

hypsochromic shift. Perhaps the more water retained with higher humidity leads to the
dehydrated protein regaining more of its native structure with a concomitant reduction in
the hypsochromic shift.
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Validation

Sensitivity

All previous data that had been collected involved the use of 7.5 μg of total protein
into a 75 μl reaction in an individual well in a 96-well plate. A range of input volumes
was tested in order to determine if the Soret band shift could still be observed with
smaller amount of input total protein. Hemoglobin spectral profiles from 1.1 – 8.8 μg of
total protein are shown in Figure 17. It can be seen from these profiles that 2.2 μg of total
protein is needed to obtain the characteristic α576nm and β541nm bands needed for the
identification of the stain as blood. As little as 1.1 μg (0.5 μl) is needed to analyze the
hypsochromic shift to determine the age of the stain (Figure 18). However, the sensitivity
of this assay was determined to be 2.2 μg of total protein since that amount was needed
for a complete hemoglobin spectral profile to be obtained. While this is not an optimal
input level, it is still sufficient to allow for a determination of the time since deposition.
The samples used in the previous experiment were simply smaller aliquots of a
standard bloodstain extract. In order to further test the sensitivity of the developed
method, bloodstains were prepared using a smaller initial volume of blood. Bloodstains
ranging in size from 10 μl down to as small as 0.2 μl were prepared (Figure 19). For the
sensitivity testing, the 0.2 – 1 μl bloodstains were extracted in only 25 μl of 0.2M TrisHCl buffer (as compared to the standard 75 μl). Initially a range of input volumes, from
10 to 120 nanoliters (0.25 – 3 μl of the 25 μl extract), from a 1 μl bloodstain extract were
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tested. The spectral profiles obtained using these input volumes are shown in Figure 20,
with the Soret band shown in greater detail in Figure 20B. While the Soret band is visible
using as little as 20 nanoliters, in order to obtain a spectral profile including the α576nm
and β541nm bands, 40 nanoliters (1 μl of the 25 μl extract) was required (Figure 20).
Since as little as 40 nanoliters was required to obtain spectral profiles of sufficient
quality for analysis, attempts were made to obtain similar spectral profiles using
bloodstains smaller than 1 μl. It was expected that the smaller bloodstains would result in
a lower hemoglobin concentration in the resulting extract and therefore increased
nanoliter volumes were tested. As can be seen from Figure 21, analysis of up to 300
nanoliters of blood from a 0.5 μl stain did not result in suitable spectral profiles including
unclear α576nm and β541nm bands (Figure 21A) and a broad Soret band (Figure 21B).
Similar results were observed with 0.75 μl even with increased nanoliter input (up to 450
nanoliters) (Figure 21C and 21D). The inaccuracy of the ΔλSoret measurements using the
0.5 and 0.75 μl bloodstains is demonstrated in Figure 22. The broadness of the Soret band
resulting from the low hemoglobin concentration of the extracts, the λSoret
measurements are significantly different from that obtained using the standard stain size
(~60 μl). Therefore the sensitivity of the ΔλSoret assay was demonstrated, allowing for
the analysis of bloodstains as small as 1 μl in size using as little as 40 nanoliters of
extract.
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Bloodstain Size

While it was necessary to demonstrate the ability to obtain accurate and reliable
ΔλSoret measurements from small bloodstains needed, it was equally as important to
demonstrate that ΔλSoret measurements would not be affected by significant larger
bloodstains. Large bloodstains or pools of blood can frequently be encountered at crime
scenes. The outer regions of the bloodstain may dry quicker than the center of the
bloodstain which contains a greater amount of blood. Therefore it is possible that
different oxidation rates could be occurring within the same larger bloodstain. Therefore,
the ΔλSoret was determined for the 60 μl bloodstains and compared to that of 600 μl
bloodstains. As can be seen from Figure 23, the large 600 μl bloodstain had a lighter
colored outer portion with a denser center portion. Samplings from the outer and central
portions of the 600 μl bloodstain were collected and the ΔλSoret determined for each. As
can be seen from Figure 24, the size of the bloodstain or the location of the sampling did
not affect the ΔλSoret allowing crime scene analysts to collect samplings from various
regions of suspected bloodstains.

Portable “Point-Of-Use” Spectrophotometer

The ability to obtain ΔλSoret measurements and characteristic blood spectral peaks
from bloodstains as small as 1 μl was previously demonstrated. However, for the ΔλSoret
assay to be of greater use in forensic casework, the ability to perform such measurements
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directly at crime scenes could be useful. This would allow investigators to identify if a
stain was blood and possibly how old the stain was prior to packaging samples to submit
to the crime laboratory for further analysis. In order to do this, a portable
spectrophotometer would have to be available at the crime scene. Recently, a portable
spectrophotometer has become commercially available from Implen called the
NanoPhotometerTM. The instrument has no moving parts making it more durable during
transport to a crime scene and weighs less than 10 lbs. Concentration measurements
(protein, DNA, RNA), full wavelength scans (190-1100nm), standard curves, ratio
calculations and kinetic measurements can be performed on the instrument with as little
as 0.7 μl of sample. The cuvette is inserted into the holder and the sample is then placed
on the top of the cuvette. The mirrored lid is then placed on top of the cuvette and the
measurement can be taken. Once a measurement is made, the sample can be collected
from the top of the cuvette and the area cleaned between measurements. The wavelength
data obtained from the instrument is provided in 1 nm intervals, which is the same
resolution that is provided by the microplate reader used in all previous studies. When a
sample measurement is taken, the data can be printed directly from a built in printer or
can be connected to a computer through a USB or Bluetooth wireless connection. If the
data is printed from the built-in printer, a small receipt-like print out is obtained. The
print out contains the date and time the measurement was made, the serial number of the
instrument is was collected on, and provides a full spectral profile including the
wavelength and absorbance of recorded peak maxima. If the data is sent to a computer,
the same data is provided in a report generated in the software that accompanies the
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instrument. Additionally, the data can be sent directly into an Excel file which creates its
own graph of the data which can then be modified.
Initial work was performed with the NanoPhotometerTM to determine if it would be
possible to obtain reliable ΔλSoret measurements. Bloodstains stored at 22oC and 50%
humidity from 15 minutes to 1 week were analyzed using the NanoPhotometer and then
compared to the original data obtained using the microplate reader. The results of this
comparison can be seen in Figure 25. The r2 value for the data set on both instruments
was above 0.9, however was slightly lower for the NanoPhotometer (0.9089) compared
to the microplate reader (0.9861). As was seen with the standard bench-top
spectrophotometer, the wavelength for the whole data set using the NanoPhotometer was
slightly higher then what was observed with the microplate reader. Again, this simply
indicated the need to calibrate any instrument before measurements with unknown
samples could be made.
Despite the slight differences observed in the r2 values obtained from data collected
using the NanoPhotometerTM, the initial data indicated the potential utility of this
instrument (or one like it) for use at crime scenes. Further validation of this instrument
may also help improve the results. An optimization of the sample volume and
concentration would need to be performed in order to determine the proper amount of
sample to use for analysis.
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Enzyme Activity Assays

As an alternative approach to the determination of the time since deposition of
dried bloodstains, the stability of enzyme activity in aged bloodstains was examined. It
was expected that a decline of enzyme activity as the age of a stain increases would be
observed and could possibly be used to estimate the age of the stain. The microplate
reader used in the ΔλSoret assay was used to perform enzyme kinetic assays with a
determination of the maximum velocity of each reaction.
Numerous candidate enzymes were selected for initial screening (Table 5). These
candidates were selected from the classical serological and human biochemical genetics
literature where they were typically analyzed by gel electrophoresis. There are several
detection methods available for use with these candidates. Initially, both fluorescence and
colorimetric detection methods were evaluated. Many of the candidates utilized a NAD
or NADP fluorescence detection scheme, which could also be coupled to a MTT
colorimetric detection scheme. Several 4-methlyumbellifry-labeled assays were also
evaluated which result in the production of a fluorescent product without the use of NAD
or NADP. Additionally, there were also numerous enzyme candidates that use a direct
MTT, NBT, or other colorimetric detection scheme.
To initially evaluate the reaction to determine if the reaction was working, 100μl
of this extract was tested with the reaction mixture. A ‘no sample’ blank was also run to
ensure that any reaction obtained was due to the enzyme itself and not enzymeindependent substrate conversion. If enzyme activity was detected, the sample input was
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varied from 5-100μl (5, 10, 20, 40, 60, 80, and 100μl). The linearity of sample input
versus MaxV (as determined by the instrument software) for fluorescence-based assays
and colorimetric-based assays was evaluated. Adjustments to sample and reagent
concentrations were made to develop an optimized reaction.
Numerous candidate enzymes were rejected for a variety of reasons (inefficiency
of assay to detect enzymes, lack of solubility/compatibility of reagents with
recommended buffers). It was determined that the colorimetric assays (detection at
565nm, for MTT-formazan reactions) provided the most reliable results and were
therefore used to examine potential activity differences between bloodstains of different
ages. Two sets of room temperature bloodstains, ranging in age from 1 month to 1 year (1
month, 3 months, 6 months and 1 year) were tested using each assay. For each assay, two
different samples for every time point were tested, and each sample was run in triplicate.
The triplicate data for each sample was averaged, and then the average for the two
samples was averaged as well to given an overall MaxV for each time point. The average
MaxV was then plotted against the age of the stain in order to determine if any trends
could be identified (Figure 26). A decrease in enzyme activity as the age of the stain
increases was observed for size enzymes, including lactate dehydrogenase, malate
dehydrogenase, phosphogluconate dehydrogenase, isocitrate dehydrogenase, glycerate
dehydrogenase, and alcohol dehydrogenase (Figure 26). The individual enzymes also
exhibited varying rates of enzyme activity loss. This initial data indicated that it might be
possible to use the amount of residual enzyme activity detected in a dried bloodstain in
order to determine the time of deposition of that stain.
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The data was also examined in order to determine the amount of time required for
a complete loss of activity to be observed for each enzyme. If the enzymes lost activity at
various times, it could be possible to determine an approximate age of an unknown stain
based on which enzymes were still active and which enzymes were lost assuming that the
protein input was normalized. The amount of time required for each enzyme to totally
lose its activity (by direct observation or by extrapolation from the activity-time graph)
is listed in Table 6. Glycerate dehydrogenase, lactate dehydrogenase, and isocitrate
dehydrogenase lost activity in slightly less than one year (10.1, 11.4 and 11.8 months
respectively). Alcohol dehydrogenase, phosphogluconate dehydrogenase, and malate
dehydrogenase lose activity between one and two years (14.4, 16.0, and 20.7 months
respectively). L-xyulose reductase and 3-hydroxybutyrate dehydrogenase lose activity
after two years or more (28.7 and 144.7 months respectively). Interestingly,
phosphoglucomutase (PGM), glucose-6-phosphate, and gluconate dehydrogenase can be
considered relatively stable enzymes which may be useful in future experiments for use
as potential normalizers or positive controls.
While this initial data requires month differences in age in order for TSD
estimates to possible be made, it did provide an indication that enzyme activity
measurements may be useful in estimating the age of the dried bloodstain. Only a small
number of enzymes were evaluated and therefore additional enzymes may require smaller
time differences for relationships to be seen and therefore provide better resolution. This
method could also be applied to other biological fluids in addition to blood whereas the
previous Soret band hypsochromic shift method is limited to bloodstains.
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CHAPTER FOUR: RESULTS – miRNA PROFILING FOR BODY FLUID
IDENTIFICATION

Presence of miRNAs in Forensically Relevant Dried Body Fluid Stains

In order to determine whether miRNAs were present in the total RNA isolated
from the stains, a reverse transcriptase-polymerase chain reaction (RT-PCR) detection
strategy was employed. Complementary DNA (cDNA) was synthesized from total RNA
using the miScript Reverse Transcription kit (Qiagen). The miRNAs were simultaneously
polyadenylated and reverse transcribed using both random and oligo-dT primers. The
oligo-dT primers contain a 5’ end universal tag which is utilized as a primer binding site
for subsequent real time PCR detection. Individual miRNAs were subsequently detected
using the miScript SYBR® Green PCR kit. Each single-plex reaction utilizes a universal
primer (complementary to the 5’ universal tag on oligo-dT primer used in the reverse
transcription reaction) and a miRNA-specific primer (Human miScript Primer Assay Set
V1.0, Qiagen). Figure 27 depicts the absolute Ct values for twenty-five miRNAs in
blood, semen, saliva, vaginal secretions and menstrual blood. The detection of numerous
miRNAs, with expression values well below the recommended 40 cycle limit, indicated
that miRNAs are present in total RNA extracts from dried biological stains.
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Identification of Differentially Expressed miRNA in Biological Fluids

Numerous studies have been published describing miRNA expression in both
normal and cancerous human tissue samples. A small number of miRNAs have been
identified as “tissue-specific,” demonstrating a high abundance in an individual tissue
with low or no abundance in others. While a majority of these studies evaluated a wide
range of human tissues they did not include, with the notable exception of blood, most of
the physiological fluids of relevance to forensic analysis such as semen, saliva, vaginal
secretions, and menstrual blood. Such body fluids typically comprise secretions from
multiple tissues and hence the resulting miRNAome would be expected to comprise
miRNAs from the contributing tissues. Moreover it is possible that a miRNA designated
as “tissue-specific” in previous studies may be found in high abundance in these
previously untested forensically relevant fluids. Therefore, we made no prior assumptions
regarding the tissue specificity of particular miRNAs. In order to identify highly
abundant or possible fluid-specific miRNAs in forensic biological stains, an extensive
survey of the expression of 452 miRNAs was conducted.
For the initial screening experiments, five-donor pooled body fluid samples were
used in order to take into account any possible inter-individual sample variation. All
samples were run in duplicate and the average Ct value was used for comparison.
Negative controls for each of the pooled body fluid samples, to which no reverse
transcriptase was added (RT-), were also run in duplicate to ensure that the miRNAs were
the source of amplification products being detected. Initially, only 50 pg of cDNA was
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used for real-time PCR based detection in order to facilitate the identification of highly
abundant miRNAs.
Graphs of absolute Ct values obtained for each body fluid were created which
allowed for an evaluation of the relative expression levels for individual miRNAs (Figure
27). No truly fluid-specific miRNAs, with high to moderate abundance of the miRNA in
a single body fluid (and no expression in the other body fluids), were identified.
However, it was evident that a significant number of the 452 miRNAs evaluated were
differentially expressed in the various body fluids. Figure 27 depicts the expression of 25
miRNAs in blood, semen, saliva, vaginal secretions and menstrual blood. Numerous
miRNAs demonstrated similar expression levels in all of the body fluids (data not
shown). However, other miRNAs demonstrated a significant difference in expression
between the body fluids. For example, miR16 (Figure 27), was found in much higher
abundance in blood and menstrual blood compared to semen, saliva, and vaginal
secretions (ΔCt ~ 8). Overall, a significant number of miRNAs (~20%) were found in
higher abundance in blood than any of the other body fluids. Numerous potential
menstrual blood (n = 38), saliva (n = 32), semen (n = 17) and vaginal secretions (n = 7)
candidates were also identified (data not shown).
During the course of the initial screening, numerous miRNAs were identified that
were not readily detected in all or most of the body fluids using only 50 pg of input
cDNA. In order to not overlook potentially useful miRNA candidates present in lower
abundance, additional screening of previously undetected or poorly detected miRNAs (Ct
> 38) was conducted using 500 pg (10-fold increase) of cDNA for detection (data not
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shown). The use of additional cDNA input resulted in the identification of additional
potential menstrual blood (n = 7), semen (n = 30) and saliva (n = 10) candidates, but
failed to identify any additional vaginal secretion candidates.
Further screening of 179 of the most abundant miRNA candidates was
accomplished by constructing an expression ‘heat map’ in order facilitate identification
of those candidates that exhibited significant differential expression between the various
body fluids (Figure 28). Examples of potential body fluid candidate miRNAs are
indicated in color (red – blood, yellow – semen, blue – saliva, green – vaginal secretions,
pink – menstrual blood). It was expected that a large number of the heat-map selected
candidate miRNAs would not ultimately be ideal for inclusion in body fluid identification
assays. For example, the expression data up to this point had not been subjected to any
rigorous normalization strategies (apart from input quantity of the total RNA isolate) and
was obtained from pooled samples rather than separate individuals. It was thus important
to evaluate other normalization strategies and the variation of expression levels between
different individuals instead of from pooled samples.

Normalization

The success and accuracy of any biological assay involving the use of quantitative
expression analysis depends on proper normalization of data. The purpose of
normalization is to minimize potential variation that can mask or exaggerate biologically
meaningful changes. Quantitative assessments of total RNA in a sample can be affected
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by various factors including extraction efficiencies of RNA from different body fluids
and substrates upon which they were deposited as well as potential RNA degradation.
The currently available RNA quantitation methods are not human-specific and therefore
RNA quantity estimations can also be affected by the presence of contaminating nonhuman species. Potential normalization strategies for use in miRNA expression analysis
include the use of housekeeping genes (mRNA), small RNAs such as 5S rRNA or U6b (a
small nucleolar RNA), and universally expressed miRNAs. Ideally a normalizer should
be present in relatively high and consistent abundance in all tissues or cell types, should
be of similar size and found in similar cellular environments as the target molecule, and
be compatible with the analysis methods utilized for the target molecule. Messenger
RNAs from housekeeping genes may not be the most suitable targets for normalization of
miRNA expression data due to abundance, degradation rates and amplimer size
differences.

Presumably

universally

(and

approximately)

equally

expressed

‘housekeeping’ miRNAs could be used as normalizers but appropriate candidates still
need to be identified by additional studies. Accordingly we used a normalization method
that involved standardization of total RNA input and measurement of the relative
expression of the miRNA in comparison to the small nuclear RNA, U6b. Total RNA
extracts were first quantitated using a RiboGreen fluorescence assay and equal amounts
of total RNA were used in subsequent reverse transcription assays. However, this
normalization strategy was not sufficiently precise enough on its own due the potential
presence of differing levels of non–human sources of RNA in some forensic samples
(e.g. bacteria in saliva and vaginal secretions). Therefore, we chose to also employ a
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delta Ct (ΔCt) metric which measured the relative abundance of a particular miRNA in
relation to the small nucleolar RNA, U6b. U6b was chosen based on its high abundance
and apparent stability in different body fluid stains of forensic interest (data not shown).
For high abundance miRNA candidates whose expression was greater than U6b, the ΔCt
metric was obtained by subtracting the Ct value of miRNA from the Ct value of the U6b,
whereas for miRNAs present in lower abundance than U6b, the ΔCt was obtained by
subtracting the Ct value of U6b from the Ct value of the miRNA.

Candidate Selection

U6b-normalized expression of the miRNA candidates with individual samples
rather than the previously-used pooled samples resulted in the rejection of several
candidates due to either too much variation between individuals or insufficient variation
between different body fluids (data not shown).

This additional screening process

resulted in the identification of differentially expressed miRNAs that were good
candidates for blood, semen, saliva, vaginal secretions, and menstrual blood.
Strong candidates were those miRNAs found in higher abundance than U6b in an
individual body fluid but present at lower levels than U6b in other body fluids. Two
strong candidates for blood, miR451 and miR16, were identified. As can be seen from the
relative expression plot in Figure 29A, expression of these miRNAs in blood (higher
abundance than U6b) was significantly higher compared to all other body fluids (lower
abundance than U6b). While no miRNAs were found in semen in higher abundance than
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U6b, two good candidates, miR135b and miR10b, were identified that demonstrated a
higher abundance in semen relative to the other body fluids (Figure 29B). Two strong
candidates were identified for saliva (miR205 and miR658) (Figure 29C). Only one
strong candidate, miR124a, was identified for vaginal secretions (Figure 29D). Two other
potential vaginal secretion candidates were identified, miR372 and miR195. Expression
of miR372 was relatively similar in all body fluids, but was found in slightly higher
abundance in vaginal secretions (Figure 29E). The other potential candidate, miR195,
was least abundant in vaginal secretions (Figure 29F). Despite its low abundance, it was
considered as a possible candidate because the near absence of this miRNA in
combination with the presence of miR124a or miR372 may be indicative of vaginal
secretions. Potential menstrual blood markers included miR451 (Figure 29G) and
miR412 (Figure 29H) chosen on the basis of differential expression compared to other
body fluids rather than being the most abundant miRNA species in menstrual blood.

Development of miRNA Body Fluid Identification Assays (miRNA BodyFluID)

While none of the miRNA candidates were found to be truly body fluid-specific
in the sense that they were expressed in one tissue and not in any other, it was
hypothesized that a panel of differentially expressed miRNAs could be used to develop a
unique expression profile that would be characteristic of an individual body fluid. For
initial assay development, normalized expression data for each of the previously
identified miRNA candidates (miR16, miR451-blood; miR135b, miR10b-semen;
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miR205, miR658-saliva; miR124a, miR372, miR195-vaginal secretions, miR451,
miR412-menstrual blood) was obtained for blood, semen, saliva and vaginal secretion
samples from different individuals (n=5). The ΔCt values were used to create twodimensional scatter plots in order to determine if differentiation of each body fluid would
be possible. Significantly, distinct clustering of each body fluid was observed for each
miRNA pair, with the body fluid of interest in each assay clearly separated from the other
body fluid expression data (Figure 30A-F). It became apparent that such differential
clustering could form the basis of a body fluid identification assay. Therefore, the nine
candidates were selected for inclusion in a miRNA panel for body fluid identification
(Table 7).
The degree of separation between the body fluid of interest and the other fluids
differed between miRNA pairs. For example the blood identification assay, using the two
strong blood miRNA candidates (miR16 and miR451), provided an approximate 7-8 ΔCt
difference in both dimensions from the next closest body fluid (Figure 30A). However,
with the vaginal secretion assays using the stronger vaginal secretions candidate,
miR124a, only a 2-3 ΔCt difference was observed between vaginal secretions and the
next closest body fluid (Figure 30D and 30E). In an attempt to improve the resolution
between body fluids for the vaginal secretion assay, a three-dimensional scatter plot was
created using miR124a, miR372 and miR195 (Figure 31). While distinct body fluid
clusters were visible using the 3D scatter plot, combination of all three miRNA
candidates did not significantly improve the distance between the various body fluid
clusters. As a result, the 2D scatter plot was determined to be sufficient for the vaginal
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secretion assay. It was decided that the miR124a-miR372 assay would be used for further
validation due the fact that miR372, while a weak candidate, still provided a positive
result. MiR195 was least expressed in vaginal secretions and considered a negative result.
The potential for false positive results can be increased with a “negative” marker if
degradation is present. For example, miR195 would be detected in a pristine blood
sample in relatively high abundance and would be clustered away from the vaginal
secretions data using this assay. However, if a degraded blood sample was analyzed and
miR195 was not detected, this would produce a “negative” result which could be
interpreted as a false positive for vaginal secretions. It is not known if the strength of the
other vaginal secretion candidate, miR124a, would be sufficient to prevent such false
positive results. Therefore, the inclusion of miR372 in the vaginal secretion assay was
deemed more appropriate.
In order to ensure that the miRNAs were the true source of the obtained
expression data, reverse transcription negative (RT-) samples, to which no reverse
transcriptase had been added, were evaluated with the miRNA panel. The average Ct
value for 10 RT- samples for each body fluid was determined (Table 8). For several of
the miRNAs including miR451, miR16, miR135b, miR10b, and miR372, no signal was
detected in any of the RT- samples. However, for the remaining miRNAs (miR658,
miR205, miR124a, miR195 and miR412), Ct values were obtained for the RT- samples
(Table 8). The average Ct value for the RT- samples for miR658, miR205, miR195 and
miR412 were slightly above 40, which is the manufacturer’s recommended maximum
number of amplification cycles, and would therefore be undetected if a 40-cycle limit was
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utilized. However, lower Ct values were observed for miR124a (avg. = 37.3) and U6b
(avg. = 35.7). While the presence of a signal in the RT- samples could be a concern, none
of the RT- signals were close to the Ct values obtained for the body fluid samples of
interest (Table 8). For example, the average Ct for miR124a for the RT+ vaginal
secretion samples (n=10) was 25.1 whereas the RT- value was 37.1, an approximately
4096 fold difference in expression. For the assays with no signal detection in the RTsamples (miR451, miR16, miR135b, miR10b, miR372), a Ct value of <50 was accepted
as a valid result. However, different detection thresholds needed to be established for the
assays where a signal was detected in the RT- sample (miR658, miR205, miR124a,
miR195, miR412 and U6b). For these assays, only Ct values below the RT- average
could be considered valid. To determine an acceptable value range for these assays, the
average Ct value minus three standard deviations (rounded to the nearest 0.5 number)
was calculated and the obtained value was used as the maximum acceptable Ct value
(Table 8). Any unknown sample whose Ct value for these assays was above the
determined threshold value was considered invalid and could not be used for further
analysis.
All valid Ct values were used to obtain ΔCt’s for each of the miRNAs included in
the body fluid identification panel. Previous ΔCt calculations were performed in such a
manner as to result in the body fluid of interest being plotted in the positive/positive
quadrant of the two dimensional scatter plot if possible. However, in an attempt to simply
analysis and to provide a more accurate representation of the expression of each miRNA
in relation to U6b, all normalization in subsequent studies was performed by subtracting
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the miRNA Ct value from the U6b Ct value. For strong candidates, whose expression was
higher than that of U6b, this would result in a positive value. For weaker candidates,
whose expression was lower than that of U6b, this would result in a negative value. As a
result, a visual examination of the constructed 2D scatter plots also provides additional
information regarding the relative abundance of each miRNA in each biological fluid.
The initial assay design demonstrated that the panel of selected miRNAs (blood –
miR451, miR16; semen – miR135b, miR10b; saliva – miR205, miR658; vaginal
secretions – miR124a, miR372; menstrual blood – miR451, miR412) seemed suitable for
the differentiation of forensically relevant biological fluids (Table 7). The miRNA based
body fluid identification assays (named ‘miRNA BodyFluID’) were thus subjected to
more extensive validation studies.

miRNA BodyFluID Specificity

Body Fluid/Tissue Specificity
The initial studies were performed using only five samples per body fluid. In
order to ensure the specificity of each assay, additional body fluid samples were tested
(n=10-20 for the body fluid of interest, n=8-10 for the other body fluids not being
assayed for).
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Blood

Nineteen human blood samples (including the five previously tested samples)
were analyzed using the blood miRNA assay (miR16/ΔCt miR451). The blood sample
donors, both male and female, ranged in age from 15 months to 84 years old. As before,
all of the human blood samples were found in a distinct cluster in the upper right
quadrant separated from all other body fluids (Figure 32A).

All vaginal secretion

samples were found in the lower left quadrant and there was considerable overlap of the
semen and saliva samples, which were spread out over the two lower quadrants and the
upper right quadrant. The buccal samples were located closer to the blood samples than
any of the other fluids but were still well separated from each other.

Saliva

Eighteen human saliva samples (including the five previously tested samples)
were tested using the saliva miRNA assay (miR205/miR658). Samples were obtained
from both male and female donors ranging in age from 26 – 58 years old, and included
both liquid whole saliva samples (n=9) and buccal swabs (n=9). As can be seen from
Figure 32B, all of the liquid saliva and buccal scrapings samples were located together in
a distinct cluster separate from the other body fluids tested. They were clustered in the
upper right quadrant with the exception of one buccal sample which, although part of the
cluster, was slightly outside the quadrant. The vaginal secretions, blood and semen
samples were mainly located in the lower left quadrant with a few samples just inside the
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lower right quadrant (Figure 32B). The ability to identify both liquid saliva and buccal
samples is an important finding since both whole saliva and buccal cells are encountered
in forensic specimens.

Semen

Eleven human semen samples (five previously tested samples included) were
tested using the semen miRNA assay (ΔCt miR135b and ΔCt miR10b). Samples were
obtained from adult males ranging in age from 26 – 52 years old. As can be seen from
Figure 32C, all of the semen samples are found in a distinct cluster separated from all
other body fluids. However, the separation between body fluids using this assay is not as
significant as was observed with the blood assay. As previously discussed, neither of the
miRNAs used in the semen assay were identified as strong candidates (i.e. found in
higher abundance than U6b) and all data points are found in the lower left quadrant
(Figure 32C). Therefore while the semen samples are found in a distinct cluster, the
identification of stronger semen miRNAs will be necessary in order to improve the
separation between body fluids.
Samples from two vasectomized males were included in the study in order to
determine if the semen assay was specific to sperm cells. Both of the samples from the
vasectomized males (orange squares) were detected amongst the semen samples from
non-vasectomized males, thereby demonstrating the ability of the assay to accommodate
non-sperm containing semen samples (Figure 32C). The detection of semen from both
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vasectomized and non-vasectomized males could indicate that the two semen miRNA
candidates are present in seminal fluid or in epithelial cells from the male reproductive
tract. Overall, fewer miRNAs were detected in semen compared to the other biological
fluids and those that were present were often found in much lower abundance. The low
abundance of these miRNAs may be explained if detection is obtained from the low level
of non-sperm cells present in semen. The cellular and non-cellular components of semen
could be separated and examined for the presence of both of the semen miRNA
candidates to determine if the miRNAs used in the semen assay are cellular based. If the
miRNAs were present in the cellular component, then sperm cells would need to be
specifically isolated from other non-sperm cells that may be present which could be
accomplished using laser capture micro-dissection. Regardless of the origin of the
miRNAs used in the current semen assay, further work will be needed to identify stronger
semen candidates and to identify possible sperm-specific miRNAs.

Vaginal Secretions

Eleven vaginal secretion samples (including the five previously analyzed
samples) were collected from adult females ranging in age from 28 – 65 years old and
tested using the vaginal secretions miRNA assay (miR124a/ΔCt miR372). As can be seen
from Figure 32D, all vaginal secretion samples, except for one ‘false negative’, were
located together in a distinct cluster in the lower right quadrant separate from the other
body fluids. Since the whole saliva sample set was the closest to the vaginal cluster,
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additional saliva samples comprising five buccal epithelial samples were tested using the
vaginal secretions assay in order to determine whether the vaginal epithelial and oral
epithelial cells were distinguishable. While the buccal epithelial cells clustered closer to
the vaginal secretion data points than the whole saliva samples, there was still a clear
separation between the two body fluids (Figure 32D). Since only one strong miRNA
candidate (i.e. more abundant than U6b) was identified for vaginal secretions, it is
possible that the separation between buccal and vaginal secretion samples could be
improved if a second strong candidate was subsequently identified.

Other Human Tissues

Despite reports in the current literature of the identification of tissue-specific
miRNAs, it has been suggested that a majority of miRNAs will be expressed in the
majority of tissues [101]. While all of the miRNAs included in the body fluid
identification panel described above were detected in each body fluid, their differential
expression enabled each of the four body fluids to be distinguished. A more detailed
study to evaluate tissue specificity of the miRNA BodyFluID assays was carried out
using a wide variety of human tissues.
Total RNA from twenty-one human tissues including adipose, brain, cervix, heart,
liver, lung, placenta, prostate, skeletal muscle, testes, thyroid, trachea, bladder, spleen,
thymus, ovary, kidney, colon, esophagus, small intestine (FirstChoice® Human Total
RNA Survey Panel, Applied Biosystems/Ambion) and skin (Biochain Institute, Inc.), was
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analyzed using the miRNA panel. Each total RNA sample included in the FirstChoice®
panel comprised RNA from at least three different donors and was certified to contain
small RNAs (miRNA, siRNA and snRNA). As expected, the miRNAs included in the
panel were detected in each of the tissue samples but again in varying abundance. The
high degree of specificity of each of the miRNA body fluid identification assays was
confirmed since all of the tissue samples exhibited expression profiles that differed from
that of the appropriate body fluid in each of the four assays (Figure 33).
For the blood assay, both miR16 and miR451 were detected in all twenty-one
tissues with the exception of the small intestine where miR451 was not detected (data not
shown). MiR451 was found in the highest abundance in lung and placenta whereas
miR16 was found in the highest abundance in lung and prostate. However, despite their
higher abundance in these tissues compared to the rest of the samples, their abundance
was still lower than that in human blood samples. When the tissue samples were
evaluated using blood assay and the data analyzed using the 2D scatter plot, all of the
tissue samples were present in the lower left quadrant of the scatter plot whereas the
blood samples were tightly clustered in the upper right quadrant (Figure 33A).
One of the saliva miRNA candidates, miR658, was present in low abundance in
all of the tissue samples (data not shown). MiR205 was present in moderate abundance in
the cervix, placenta and prostate tissue but in low abundance in all other tissues. The 2D
plot showed the tissue samples located in the lower left quadrant with a significant
separation from the saliva samples, which were located in the upper right quadrant
(Figure 33B).
68

Both the semen candidates, miR135b and miR10b, were also detected in all of the
twenty-one tissues with many present in moderate to high abundance. MiR135b was
detected in highest abundance in testes and thyroid, whereas miR10b was detected in
high abundance in numerous tissues including testes, adipose, cervix, ovary, kidney and
colon. As a result of the high abundance of these miRNAs in numerous tissues, the
separation between the human semen sample cluster and the tissue samples was not as
great in the 2D scatter plot as that observed for the blood assay (Figure 33A and 33C). As
can be seen from Figure 33C, the tissues are all present in close proximity to the human
semen samples although still distinct there from. This data indicates the need to monitor
the continually-expanding miRNAome for more specific semen candidates.
For the vaginal secretions assay all tissue samples were located in the lower left
quadrant separated from the vaginal secretions samples that were located in the lower
right quadrant (Figure 33D). Several published studies have identified miR124a as a
brain-specific miRNA [56,58,59]. While miR124a was found in highest abundance in
brain compared to the other tissues examined, the expression level observed in brain was
still lower than that we observed for vaginal secretions. Due to these differences in
expression, the brain sample was located closer to the vaginal secretions samples on the
two-dimensional plot but was still present in the lower left quadrant (Figure 33D). The Ct
values for miR372 ranged from 32 to >40 for all tissue samples, with the lowest Ct value
obtained from placenta. So despite the presence of only one strong candidate, the
specificity of this assay for vaginal secretions is supported by the tissue data.
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Species Specificity
Optimal forensic analysis not only requires an assay to possess tissue specificity
but it also should exhibit restricted species specificity. To check this, a number of nonhuman blood samples were analyzed including twelve animal species (dog, cat, horse,
crane, cow, coyote, sheep, tortoise, lamb, Patagonian cavy, ferret, deer) and ten nonhuman primate species (spider monkey, rhesus macaque, pig-tailed macaque, brown
lemur, chimpanzee, baboon, howler monkey, cynomolgus monkey, African green
monkey, spot-nosed guenon). A smaller number of non-human saliva samples were
available tested and included cat, dog and one primate (spot-nosed guenon). Semen and
vaginal secretion samples from non-human species were not available for testing, but
such body fluids from non-human species are rarely encountered in casework.
For all of the non-human species blood samples, miR451, miR16, and U6b were
detected in significant abundance. As can be seen from Figure 34A, all of the non-human
samples were found in close proximity to the human blood data points. Two animals
(ferret and coyote) and four primates (chimpanzee, baboon, African green monkey, and
cynomolgus monkey) were located directly within the human blood cluster (Figure 34A).
While only a small number of the species tested were clustered within the human blood
samples, the small distance between the human data points and the remaining animal
species would make it difficult to differentiate human and non-human blood samples with
any degree of confidence using this assay.
Saliva samples from two dogs and two cats were used to examine the species
specificity of the saliva miRNA assay. As can be seen from Figure 34B, negative results
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(i.e. not found in the human saliva data cluster) were obtained for the both of the cat and
dog samples. While an extensive number of animal saliva samples were not available for
testing, cat and dog represent animals that could be frequently encountered at crime
scenes in forensic casework. One primate saliva sample from a spot-nosed guenon was
also tested using the saliva miRNA assay. However, the U6b value for this sample was
invalid (Ct > 34.5, Table 8) and therefore could not be used in further analysis.
As a result of the poor species specificity of the original blood assay, it was
evident that modifications would need to be made in order to provide a more forensically
relevant assay. Attempts were made to identify an alternative small RNA to be used for
normalization of the miRNA expression data that would also allow for a differentiation of
human and non-human blood stains. The expression of 11 small nucleolar RNAs
(snoRNAs), including U26, U27, U28, U29, U30, U31, U38B, U43, U44, U48 and U90,
was examined in both human and non-human blood samples in order to determine if a
human specific normalizer could be identified (Table 9). Several of the snoRNAs,
including U26, U28, U30, U44, and U90, were found in very low abundance or were not
detected in the non-human samples. However, the abundance of these snoRNAs in the
some of the human body fluids was also quite low (Table 9). For example, the Ct value
for U44, U26, U28, and U90 in semen was over 40 whereas the Ct for U30 was
acceptable for semen but was close to 40 for blood and saliva (Table 9). Therefore, none
of the snoRNAs tested were determined to be suitable for use a universal normalizer for
all body fluids.
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While an alternative universal normalizer was not identified, several of the
snoRNAs, including U26, U28 and U44, were present in low abundance in non-human
blood samples and in higher abundance in human blood samples. Therefore, it was
possible that one of these snoRNAs could be used to normalize only the blood assay and
provide the desired species specificity. U44 was selected as the top snoRNA candidate
due to its high abundance in blood, its low abundance in the animal blood samples, but
also because of its low abundance or absence in most of the primate samples. When the
2D scatter plot was constructed using the U44-normalized data, the clustering that was
achieved with the U6b-normalized assay was not achieved and overlap of the semen,
saliva and blood data was observed (data not shown). However, it was evident from the
2D scatter plot that there was a clear separation between the human blood data points and
the non-human blood samples (Figure 35). As can be seen from the U44-normalized
scatter plot, only chimpanzee was found clustered with the human blood data points
(Figure 35). Based on these results, it was determined that the U44-normalized assay
could be used to identify the presence of human or higher primate blood if a positive
result for an unknown sample was obtained using the U6b-normalized blood assay.
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miRNA BodyFluID Stability

Environmentally Compromised Samples
Forensic biological evidence is often exposed to various damaging environmental
influences including heat, light, humidity and rain. In order for an assay to be useful in
forensic casework, the ability of the assay to accommodate environmentally impacted
samples must be demonstrated. Until recently, the analysis of biological samples in
forensic casework has largely been limited to DNA-based methods. Therefore, numerous
studies have been published that demonstrate the ability to recover genetic profiles from
degraded or compromised samples. The use of RNA in forensic assays, however, has
only recently been proposed and therefore few studies have examined the stability of
RNA in forensic biological samples. Recently, we have reported the results of an
extensive evaluation of the persistence and stability of mRNA in forensic samples in
which it was demonstrated that mRNA profiling can be performed successfully on
environmentally impacted biological stains [11]. While mRNA stability was
demonstrated in samples stored at room temperature, heat and humidity appeared to be
detrimental to RNA stability [11]. However, since mRNAs are significantly larger in size
compared to miRNAs, it was therefore hypothesized that miRNAs could be less
susceptible to degradative processes due to their significantly smaller size and thus
potentially be better suited for the analysis of environmentally impacted forensic samples.
A recent study has reported more robust isolation and analysis of miRNAs compared to
mRNAs in FFPE tissue samples [102].
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In order to assess the stability of miRNAs and to determine if the miRNA assays
could accommodate environmentally impacted samples, body fluid stains were exposed
to varying storage conditions such as storage at room temperature (22oC), storage at
37oC, exposure to heat, light, humidity, and rain (outside uncovered, OUC), and exposure
to heat, light and humidity (outside covered, OC). The samples were collected at various
time intervals and the following samples from each condition were examined in this
study: room temperature – 1 year, 18 months or 2 years (2 year sample examined for
blood only); 37oC – 3 months, 6 months; outside uncovered (i.e. directly exposed to any
precipitation) – 1 day, 3 days, 1 week; outside covered (i.e. protected from direct
exposure to precipitation) – 3 days, 1 week, 1 month. Table 10 provides a summary of the
range of temperatures and humidity levels that the samples were exposed to, in addition
to the amount of precipitation (rainfall) that was observed during collection of the outside
uncovered samples. The samples placed outside were typically exposed to average high
temperatures of greater than 90oF and average high humidity levels of greater than 85%.
All samples placed outside and uncovered were exposed to various amounts of rain. After
one week of storage the blood, semen and saliva samples had received 2.7 inches of rain
and vaginal secretions samples had received 7.6 inches of rain. Total RNA was recovered
from each of the above mentioned samples in sufficient quantity for analysis and the
miRNA panel was used to determine if the presence of the body fluid of origin could be
detected. The results of this study are summarized in Table 11 and depicted in Figure 36.
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Blood

A positive result for blood was obtained for samples stored at room temperature
for 2 years and 37oC for 6 months whereas the outside (both covered and uncovered)
gave results at 1 week (Table 11, Figure 36A). All samples generating a positive result
were located in upper right quadrant cluster with the known human blood samples
(Figure 36A). The sample stored at 37oC for 3 months was also located in the upper right
quadrant but was significantly separated from the human blood cluster closer to the
location of the saliva samples (Figure 36A). Again, the appearance of the 37oC 3 month
sample near the location of the saliva samples does not indicate that this sample would be
identified as saliva. It simply indicates a negative result for blood for this sample as blood
is the body fluid being tested using this assay. However, to ensure that the 37oC 3 month
sample would not be identified as a saliva sample, the location of this sample on the
saliva two-dimensional scatter plot was determined after testing with the miRNA saliva
assay. A negative result for saliva was obtained (data not shown). Despite the false
negative result for blood obtained for the particular 37oC 3 month sample and the OUC 3
day sample, other samples stored at each condition for a longer period of time (37oC 6
months, OUC 7 days) provided a positive result (Table 11, Figure 36A). Such sample
variability could be due to differing microbiota colonization of the stains.

The

identification of blood in the most exposed sample for each condition (room temperature
2 years, 37oC 6 months, OC 1 week, OUC 1 week) demonstrates the excellent stability of
the blood miRNA candidates.
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Saliva
Saliva was detectable up to a year at room temperature (22oC) (Table 11, Figure
36B). The recovery of miRNAs from the saliva samples stored at the other environmental
conditions was significantly reduced compared to the other body fluids. The negative
results in four of the samples (two stored at 37oC and the 3 day and 1 week OC) were due
to the non-detection of the U6b normalizer and not the absence of detectable miRNA
species. The failure to detect U6b was somewhat surprising since U6b was detected in the
other body fluids under the same storage conditions. A reduced expression of miR205
was observed for all samples stored outside both covered and uncovered (data not
shown).

Semen

A positive result for semen was obtained for samples stored at room temperature
for 18 months and 37oC for 6 months whereas the outside samples gave results out to 1
week (covered) and 1 day (uncovered) (Table 11, Figure 36C). All samples for which a
positive result were obtained were located in the upper portion of the lower left quadrant
clustered with the known human semen samples (Figure 36C). For the three samples with
the negative result, U6b and miR10b were detected, however a Ct value of over 40 was
obtained for miR135b for the OUC 3 day and 7 day samples and was undetected for the
OC 1 month sample. The OUC 3 day sample, located near the vaginal secretion data, was
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tested using the vaginal secretions assay to ensure that a false positive result would not be
obtained. A negative result for vaginal secretions was obtained (data not shown). The
ability to identify semen in samples stored at 37oC for 3-6 months and stored outside for
1 week with exposure to almost 3 inches of rain and high temperatures and humidity
demonstrates a high degree of stability of the miRNA biomarkers used in the semen
assay. The detection of U6b and miR10b in the samples for which a negative result was
obtained indicates that the stability of this assay could be even more improved if a better
candidate were to be identified that could replace miR135b.

Vaginal Secretions

A positive result for vaginal secretions was obtained for samples stored at room
temperature for 18 months and 37oC for 6 months whereas the outside covered samples
gave results out to 3 days (Table 11, Figure 36D). The failure to detect miRNA in the
outside uncovered samples could be due to sample wash out by the amount of rain that
these samples were exposed to (e.g. the 1 week sample received over 7 inches of rain).
In general, miRNAs appeared to be relatively stable in all body fluid samples
stored at room temperature and 37oC for extended intervals. While exposure to
environmental elements such as heat, humidity, light and rain appeared to be detrimental
for the recovery of miRNAs in saliva and vaginal secretions, blood and semen were not
as adversely affected. It is not possible to preclude the possibility that the poor results
with saliva and vaginal secretions are due to the overrepresentation within these samples
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of co-extracting commensal or exogenous microbiota-derived RNA, the quantity of
which is expected to increase with time in environmentally exposed samples. The results
of this initial work indicate a high degree of stability for some of the miRNA candidates
and indicate their potential suitability for their use with forensic casework samples.

Menstrual Cycle
The final study conducted to evaluate the stability of the miRNA BodyFluID
assays involved an assessment of the identification of vaginal secretions in samples
collected daily during a full 28-day cycle. Menstrual cycles are controlled by a complex
interaction of numerous hormones that affect gene expression levels and therefore it is
possible that the expression of certain miRNAs may also vary. Additionally the onset of
menopause in older females results in a significant disruption and eventual complete loss
of regular hormone levels. In order to ascertain whether changes in female reproductive
hormone levels would affect the identification of vaginal secretions using the miRNA
assay, vaginal swabs from a female experiencing regular menstrual cycles and from a
female in perimenopause were collected daily for a 28-day period. For the menstruating
female, day 1 was indicated by the start of menstruation.
As can be seen from Figure 37, vaginal secretions were identified in all samples
from both the menstruating female (Figure 37A) and the female in perimenopause
(Figure 37B). All samples were located in the lower right quadrant clustered with the
known vaginal secretion samples. The samples with reported menstrual blood also were
78

positive for the presence of vaginal secretions (Figure 37A). However this is expected
since menstrual blood will contain vaginal cells and secretions. Thus no significant
changes in the expression of the vaginal secretions miRNA candidates were observed
during different female reproductive stages and also during regular menstrual cycles.

Simulated Forensic Casework Samples

The initial studies described above demonstrated the sensitivity (50pg of input
cDNA), specificity (no cross-reactivity with human tissues) and stability (detection in
environmentally compromised samples) of the developed miRNA assays for body fluid
identification. However, forensic evidentiary items may contain only trace amounts of
genetic material and may also include the presence of multiple different biological fluids.
Thus it is important to test the performance of the miRNA BodyFluID assays with such
samples and we accomplished this by the preparation and analysis of simulated casework
samples.

Saliva
Genetic profiles can be routinely recovered from trace amounts of salivary fluids
from items such as used cigarette butts and beverage containers. Therefore if the presence
of trace amounts of saliva could be detected on these items, it may provide investigators
with an indication of which evidentiary items may be useful for the subsequent recovery
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of DNA. Furthermore, saliva recovered from the skin of a victim could be useful in the
investigation of oral assault cases. In order to determine if the saliva miRNA assay could
detect trace amounts of saliva in such samples, total RNA was recovered from swabs of
beverage container lids, human skin on which saliva had been deposited, and used
cigarette butts. All of the simulated casework samples, except for one of the swabs taken
from a beverage container lid, were located clustered with the known human saliva
samples in the upper right quadrant (Figure 38A).

Blood
Total RNA was recovered from the cotton pad of an adhesive bandage used to
cover a small cut on the finger of a female donor. The cotton pad of the bandage
contained blood in the form of a small reddish-brown stain. When the bandage sample
was evaluated with the blood assay, the sample data was located in the upper right
quadrant on the two-dimensional scatter plot clustered with the known blood samples
(Figure 38B). The same sample was subsequently evaluated with the U44-normalized
blood miRNA assay in order to determine if the blood present on the bandage was of
human origin. The location of the sample on the two-dimensional U44-normalized scatter
plot was upper right quadrant clustered with the known human blood samples confirming
the presence of human blood present on the bandage (data not shown).
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Semen and Vaginal Secretions
A significant number of samples processed in an operational forensic DNA
laboratory involve the analysis of evidence recovered from sexual assaults. Often only a
small amount of semen from the perpetrator will be present amongst a vast excess of a
female victim’s biological material. For an assay to be useful in forensic casework, it
must be able to detect the small amount of semen that may be present and not be masked
by the excess vaginal material present. In order to determine the potential utility of the
semen miRNA assay for the analysis of sexual assault evidence, a vaginal and
cervicovaginal swab was collected from a female donor 18 hours post-coitus. The vaginal
and cervicovaginal swabs were collected in order to determine if semen would be
detected in different regions of the vaginal canal. To insure that residual semen from
prior sexual relations were not present, a pre-coital cervicovaginal swab was also
obtained before coitus commenced but after an abstinence period of seven days. The
presence of semen was detected on both the vaginal and cervicovaginal swabs taken 18
hours post-coitus (Figure 38C). The pre-coital swab was negative for the presence of
semen (Figure 38C). The presence of vaginal secretions was detected in the vaginal swab,
cervicovaginal swab and the pre-swab using the vaginal secretions assay (data not
shown).
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Body Fluid Mixtures
Body fluid mixtures other than the common semen-vaginal secretions
encountered in sexual assault cases may also be present in forensic evidentiary samples.
Thus additional body fluid mixtures samples, including two blood-semen (Figure 39) and
one semen-saliva (Figure 40) mixtures were also evaluated. The miRNA expression
profile for each mixture using all four body fluid assays (blood, semen, saliva, and
vaginal secretions) was determined. Blood and semen were correctly identified in both of
the blood-semen mixture samples (Figure 39). On the blood assay, the admixed samples
were located in the upper right quadrant clustered with the known blood samples (Figure
39A). On the semen assay, the samples were located in the upper portion of the lower
right quadrant clustered with the known semen samples (Figure 39C). The absence of
saliva and vaginal secretions was also demonstrated with the blood-semen mixture
samples located in the lower left quadrants (Figure 39B and 39D). Semen and saliva were
also correctly identified in the semen-saliva mixture sample with the sample clustered
with the known samples on each plot (Figure 40B and 40C). The absence of blood and
vaginal secretions was also demonstrated (Figured 40A and 40D).

Development of a Menstrual Blood miRNA BodyFluID Assay

The ability to detect the presence of menstrual blood may prove invaluable in
certain forensic cases, such as in sexual assault investigations, where the facts of the case
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may be in dispute. For example, the presence of a victim’s blood on the clothing of a
potential rape suspect may be explained as venous blood originating from a nose bleed
resulting from a physical, rather than sexual, assault of the victim. However, if the blood
was determined to be menstrual blood, it would indicate a more intimate contact between
the victim and a potential suspect.
During the female reproductive cycle, if fertilization does not occur hormonal
changes catalyze the breakdown of the endometrium lining of the uterus. Menstrual
discharge therefore consists of tissue from the degenerating endomentrium as well as
blood resulting from associated blood vessel rupture as the endometrium breaks away
from the uterus. Menstrual blood is thus a complex mixture consisting of endometrium
derived stromal, epithelial, endothelial, vascular smooth muscle, and bone marrow
derived cells, as well as capillary blood [103,104]. Menstrual blood will therefore contain
products that would also be detectable in venous blood or vaginal secretions. Menstrual
blood samples were examined using the miRNA assays for all body fluids in order to
determine if the menstrual blood samples would interfere with the identification of the
body fluid of interest on each assay (Figure 41). The menstrual blood samples were
separately clustered compared to venous blood using the miRNA blood assay (Figure
41A). As can be seen from Figures 41B and 41C, the menstrual blood samples on the
semen and saliva assays also did not overlap with the body fluid of interest. However
when the menstrual blood samples were evaluated using the vaginal secretions miRNA
assay, the presence of vaginal secretions was identified in many of the samples (Figure
41D). While this is not necessarily a false positive result since menstrual blood samples
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will contain vaginal secretions and cells, it demonstrates the need for a separate assay to
be developed that would allow for menstrual blood and vaginal secretions samples to be
distinguished.
During the initial screening of the 452 miRNAs several candidates for the
identification of menstrual blood were identified. MiR451, which is used in the blood
assay, was also present in high abundance in menstrual blood as well. Most of the
miRNAs demonstrating a moderate to high abundance in menstrual blood were also
found in significant amounts in blood or vaginal secretions. Therefore, while two specific
miRNA candidates for menstrual blood (i.e. higher abundance in menstrual blood than
U6b) were not identified, an assay was developed using miR451 and miR412 that
nevertheless permitted a distinct clustering of menstrual blood samples separate from all
other body fluids (Figure 42A). As can be seen from Figure 42A, both the venous blood
and menstrual blood samples are located in the lower right quadrant with a majority of
the other body fluid samples located in other quadrants. Two of the menstrual blood
samples were not located within the cluster of other known menstrual blood samples
(Figure 42A). While one of these samples was present in the lower right quadrant, it was
not located within the cluster of menstrual blood samples (Figure 42A). A false negative
result was obtained from the other menstrual blood sample that was located in the lower
left quadrant (Figure 42A). Despite these two discordant samples, a clear distinction can
be made between the venous blood and menstrual blood samples. There is no overlap
between the menstrual blood and vaginal secretions samples with the vaginal samples
located in the lower left quadrant (Figure 42A). Importantly, therefore, a menstrual blood
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sample should provide a positive result for the vaginal secretion and menstrual blood
assays whereas a vaginal secretions sample should only provide a positive result on the
vaginal section assay. The specificity of the menstrual blood assay was further
demonstrated with the location of all twenty-one previously tested tissue samples located
in the lower left quadrant clearly separated from the known menstrual blood samples
(Figure 42B).
Similar to the vaginal secretions assay, the expression of the menstrual blood
miRNA candidates during a 28-day period (Day 1 = first day of menstruation) were
evaluated to ascertain whether significant changes in expression would occur. Menstrual
blood was reported on days 1 – 4, with a significant reduction in the amount of menstrual
blood present on day 4. As can be seen from Figure 43, menstrual blood was detected in
the day 1 – 3 samples but was not detected in the day 4 sample. All other samples
collected during the 28-day period (days 5 – 28) were also negative for the presence on
menstrual blood (Figure 43).
Venous blood and vaginal secretions were located at opposite ends of the twodimensional scatter plot in the lower right and lower left quadrants respectively (Figure
42-44). Since menstrual blood was located somewhat in between these two body fluid
clusters, it needed to be demonstrated that a mixture of venous blood and vaginal
secretions would not be located within the cluster of menstrual blood samples. When two
different venous blood-vaginal secretion mixtures were evaluated with the menstrual
blood assay, both were located in the lower right quadrant clustered with the known
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venous blood samples (Figure 44). This further supported the specificity of the developed
assay for menstrual blood.

miRNA Profiling Schema for the Analysis of Unknown Biological Samples

A proposed experimental schema for the analysis of biological stains of unknown
origin using the miRNA body fluid identification assays is provided in Figure 45. First,
total RNA is isolated from an unknown biological stain. The use of a standard guanidine
isothiocyanate-phenol:chloroform based extraction method allowed for the recovery of
miRNAs in total RNA extracts. Numerous non-organic, silica-based extraction kits are
now commercially available for the recovery of miRNAs and, in contradistinction to the
phenol-chloroforms methods, are easily transferable to an automated platform. Thus these
kits may prove more suitable for use in forensic casework although the quantity and
quality of the recovered miRNAs from forensic stains would have to be evaluated in
separate studies. An appropriate amount of total RNA (~1-5ng) would be used for
reverse transcription (RT) (e.g. the miScript system from Qiagen). Unlike other
commercially available miRNA systems that employ miRNA-specific reverse
transcription strategies, the miScript system allows cDNA to be produced from all RNA
species within the sample, including mRNAs and other small non-coding RNAs. This
could be advantageous in forensic casework where multiple individual reverse
transcription reactions required to analyze a sufficient amount of miRNAs may not be
possible due to a limited amount of genetic material recovered from most evidentiary
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items. The ability to simultaneously reverse transcribe other RNA species, such as
mRNAs, may also be useful if parallel assays need to be performed for the detection of
tissue specific mRNAs or housekeeping genes. An appropriate volume of the RT product
to obtain 50pg (for the blood, saliva, vaginal secretions and menstrual blood assays) or
500pg (for the semen assay) cDNA would be used in the miRNA quantitative real time
PCR (QT-PCR) assay which, in our case, uses the miScript SYBR Green PCR system
and a miRNA specific primer. The detection of each miRNA must be performed in a
separate reaction well since all assays utilize SYBR Green for detection and therefore
cannot be multiplexed. However, the entire miRNA panel (9 miRNAs and 2 normalizers,
U6b and U44) can be analyzed from a single RT product. So while the miRNAs cannot
be analyzed in a multiplex format, numerous RT reactions are not required for the
examination of multiple miRNAs in the same sample. The Ct values for each miRNA are
then evaluated to ensure all obtained values are within acceptable ranges (Table 8). Any
data not within the acceptable range is rejected and would need to be repeated. All
acceptable expression data would then be normalized using U6b in which the Ct value of
the miRNA is subtracted from the Ct value of U6b. The ΔCt values for the two miRNAs
for each body fluid would then be used to position the unknown sample on the twodimensional scatter plot for each body fluid. The identification of the presence of the
body fluid would be confirmed if the unknown sample was found within the cluster of
known body fluid samples. If a positive result is obtained for blood, ΔCt values using
U44 for miR451 and miR16 would then be calculated and used to determine the species
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of origin. The presence of human (or higher primate) blood would be indicated by the
presence of the unknown sample within the cluster of human blood samples.
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CHAPTER FIVE: RESULTS –ENHANCED PROFILING STRATEGIES
FOR LOW TEMPLATE SAMPLE ANALYSIS

Low Template Samples

Short tandem repeats (STRs) are regions of repetitive DNA where the repeat unit
is 2-6 bases in length. The number of repeat units differs between individuals. For
autosomal STR loci, one or two alleles can be present at a single locus, providing a
homozygous or heterozygous genotype respectively. For standard samples (> 500pg of
input template DNA), profile recovery and analysis is relatively straightforward.
However, forensic casework evidentiary items often contain less than 100 pg of template
DNA, which is equivalent to approximately 15 diploid or 30 haploid cells. The presence
of such low template samples could be due to several factors including: damaged or
degraded DNA, oligospermic or aspermic perpetrators or from extended interval post
coital samples, where sperm have been lost over time due to the effects of drainage or
host cell metabolism. Other trace biological evidence will also contain small quantities of
cells, including fingerprints, particulate matter, and aerosols [105-107]. Since only a
small number of cells are present in LCN (short tandem repeat) methods and often results
in total failure or recovery of a partial profile.

If partial profiles are recovered,

interpretation of the data obtained from these LCN analyzed samples requires novel
considerations [64-66]. The occurrence of allelic drop-out or drop-in is significantly
higher in LCN samples due to stochastic effects, and can result in false homozygous
classifications and in false heterozygous classifications, respectively (Figure 46).
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Additionally, LCN samples exhibit significant peak height imbalance and are more
susceptible to interference from contamination (Figure 46). The frequency of LCN
samples in forensic casework warrants development of additional methodologies to ICN
that allow for more successful recovery of genetic information.

Laser Capture Micro-dissection

Laser capture micro-dissection is a technology that allows for the isolation of
single cells or groups of cells from various samples. The use of laser capture microdissection was employed in this study in order to accurately control the number of cells
being analyzed in an individual sample. Several laser capture micro-dissection
instruments are currently available that utilize either a direct contact or no-contact microdissection approach. Direct contact laser capture micro-dissection instruments involve a
laser being positioned and fired directly over the cells of interest. This approach may
cause damage to targeted cells, particularly if only a small number of cells are collected.
No-contact laser capture micro-dissection instruments use a laser to cut around the cell of
interest thereby reducing any potential damage that may be caused to the sample by
exposure to direct laser contact. For the current work, a direct contact (Arcturus PixCell
II) and a no-contact (Leica LMD) laser capture micro-dissection instrument were
available for comparison. Each instrument was evaluated for ease of use, time and labor
intensity, amenability to downstream applications and recovery of genetic profiles from
micro-dissected cells.
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Arcturus PixCell II System
The Arcturus PixCell II system utilizes direct-contact laser capture microdissection. A specimen on a standard glass microscope slide is prepared and dehydrated.
The slide is positioned on the stage of the instrument and held in place by a small
vacuum. The stage is then manipulated by a joystick attached to the stage. The highest
provided magnification objective is 40X (400x magnification). Cells of interest are
brought into focus and the laser power and pulse duration can be adjusted. For sample
collection, a sample cap is used that is coated with a thermoplastic polymer. The sample
cap is placed directly onto the specimen slide and the laser is fired over cells of interest
(Figure 47A). The laser causes the thermoplastic film to “melt” over the cells of interest.
As the film quickly cools, the cell is attached to the film and can be removed from the
specimen slide by lifting the cap off the surface (Figure 47B). The cap can be placed onto
a clean glass slide in order to ensure that the cells have been removed from the specimen
slide and are present on the cap surface (Figure 47C). A plastic ExtracSureTM device
containing a hollow center is placed over the cap. Lysis buffer is then added into the
ExtracSureTM device covering the sample area with the collected cells of interest. A
0.5mL tube is then placed over the ExtracSureTM device. A pre-heated heat block is then
placed over the sample tray and placed into an incubator for lysis.
The direct contact laser-capture micro-dissection approach of the Arcturus
PixCell II system provides the ability to isolate cells from standard glass slides. This
would allow for the collection of cells from archived casework slides. However, several
challenges with sample collection using the Arcturus PixCell II system were encountered.
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If any moisture was present in the sample, the thermoplastic film would not adhere to the
cells. The dehydration steps of the staining procedure had to be repeated in order for the
cells to be collected. Often times the additional dehydration steps did not result in
successful removal of cells from the prepared slides. On numerous occasions due to the
extremely high humidity occurring during Florida afternoons, the slide would acquire
moisture during sample collection and therefore would need to be re-dehydrated before
additional cells could be collected. Additionally, the size of the laser pulse could not be
made small enough to target the size of a sperm cell. Therefore if a sperm cell was
adhering to an epithelial cell (Figure 48A), the size of the laser pulse caused the
thermoplastic film to coat the sperm cell and a portion of the epithelial cell (Figure 48B).
When the cap is lifted, the epithelial cell was collected with the sperm cell (Figure 48B
and 48C). The lysis protocol for the PixCell II samples had to be amendable to being
performed in an incubator, with no direct contact between the sample and heat. The
sample and lysis buffer were enclosed in the plastic ExtracSureTM device. When the lysis
is completed the entire sample device has to be inverted and centrifuged in order to
collect the sample into the 0.5mL tube. Using various direct lysis methods, hundreds of
cells were needed for a partial profile to be recovered using the Arcturus PixCell II
system (data not shown).
It was possible that the small amount of nuclear material obtained from lysis of a
small number of cells was adhering to the walls of the ExtracSureTM chamber and
therefore was lost during sample manipulation. Collection into a 0.5mL tube also
required the cell lysate to be transferred to a 0.2mL PCR tube for amplification increasing
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the potential for sample loss. Additional collection strategies were attempted in order to
reduce the amount of sample manipulation and potential sample loss. The collection area
in the thermoplastic film was cut out from the cap surface and the film with attached cells
was placed directly into a 0.2mL or 0.5mL tube containing an appropriate amount of lysis
buffer. The tubes could then be placed in a heat block or thermocycler for direct contact
with heat during the lysis protocol. Additionally, excess film outside of the collection
area on the cap surface was removed and the lysis buffer placed directly on the remaining
film area where cells were attached. A 0.5mL tube was placed over the cap without the
use of the ExtracSureTM device and the lysis performed in an incubator. These modified
approaches provided only a slight improvement in profile recovery (data not shown) and
required a significant amount of sample manipulation and the use of a disposable scalpel.
These methods would not be amenable to the current requirements and resources of
operational casework laboratories and therefore no further work was performed using the
Arcturus PixCell II system.

Leica LMD
The Leica LMD system utilizes no-contact laser micro-dissection. A specimen is
heated fixed to a slide covered with a proprietary membrane and stained. As a result of
the need for samples to be placed on the membrane slides, cells could not be easily
collected from archived casework glass slides. The highest provided objective for the
Leica LMD system is 63x (630x magnification) allowing for easier viewing of sperm cell
93

samples. The slide is placed sample side down into the slide holder and inserted onto the
microscope stage. Manipulation of the stage, microscope focus, light intensity and
magnification power are all controlled by a joystick separate from the microscope itself.
Underneath the stage are the sample collection tubes. There are four chambers where a
flat-capped 0.2mL PCR tube is placed. A small volume of lysis buffer is placed in the
sample cap. The power and speed of the laser, as well as the cap position, are all
controlled in the software provided with the instrument. Cells of interest are brought into
focus (Figure 49A) and then outlined using pre-made shapes or drawn by hand (Figure
49B). The laser then cuts along the specified paths and cuts out the cells of interest from
the surrounding membrane (Figure 49C). The cells will then fall by gravity into the
sample collection tube located underneath the stage. Once samples have been collected,
the tubes can be closed and briefly centrifuged. The lysis can then be performed in a
thermocycler and subsequent amplifications can be performed in the same tube.
The no-contact laser capture micro-dissection approach of the Leica LMD
systems eliminates potential damage to cells by direct exposure to the laser. Due to the
ability of the laser to cut around a small area, an individual sperm cell head can be
outlined and cut by the laser (Figure 49). This allows sperm cells adhering to epithelial
cells to be isolated without collecting the nucleus of the epithelial cells as well (Figure
50). This is a significant advantage over the PixCell II system particularly when dealing
with sexual assault evidence where sperm may frequently be found adhering to epithelial
cells. The ability to collect cells into 0.2mL PCR tube allows for the lysis to be performed
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in thermocycler with more precision temperature control and allows for subsequent
amplifications to be performed in the same tube.

Direct Lysis Strategies

Experiments were conducted to evaluate various direct lysis buffers in order to
determine which buffer was the most efficient for epithelial and sperm cell lysis (data not
shown). Various proteinase K and alkaline lysis buffers were tested, as well as several
commercially available lysis buffers including the Quick ExtractTM lysis buffer
(Epicentre), Lyse-N-Go (Pierce), and DNAzol® Direct (Molecular Research Center, Inc).
In order to evaluate these lysis buffers, cell suspensions were prepared from semen and
buccal epithelial cell swabs. Cell numbers were determined using by cell counting using a
hemacytometer. Serial dilutions of each extract were prepared, ranging from 1 to 10001500 cells. The cell suspensions were lysed with the appropriate buffer and reactions
conditions (obtained from published materials or manufacturer’s protocols). The samples
were amplified with Profiler Plus® (standard conditions) in order to determine the
efficiency of lysis using each buffer. Those buffers that allowed for recovery of partial to
full profiles from smaller numbers of cells were further examined. In order to ensure that
the lysis buffer was responsible for the lysis of the cells, lysis buffer was added to a small
aliquot of a cell suspension. This was placed in a hemacytometer and the cell lysis was
observed under the microscope as it occurred. Two of commercially available lysis
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buffers, Quick ExtractTM and Lyse-N-Go, resulted in the most efficient cell lysis (data not
shown).
The two commercially available lysis buffers, Quick ExtractTM and Lyse-N-Go
were then further evaluated in order to determine which buffer would be most suitable for
use with LCM samples. Both buffers required only a small volume to be used (10-15μl)
and used a short lysis protocol (8-30 minutes). The use of the Quick ExtractTM lysis
buffer required the use of an alternative polymerase, the Expand High Fidelity
polymerase. The High Fidelity polymerase is a mixture of Taq polymerase and Tgo
polymerase. The Tgo polymerase is a “proofreading” enzyme, possessing a 3’-5’
exonuclease activity. It is reported that the use of this mixture of polymerases results in a
three-fold greater accuracy than Taq alone. The Lyse-N-Go buffer allowed for
amplification with Taq Gold. Both buffers allowed for recovery of STR profiles from
LCM samples; however fewer cells were required with the Quick ExtractTM buffer with
the alternative polymerase (data not shown). Additionally, increased amounts of allele
drop-in were observed for the Lyse-N-Go buffer (data not shown). Therefore it was
determined that the Quick ExtractTM lysis buffer would be most suitable for use with
LCM samples. Optimization of the Quick ExtractTM lysis buffer was performed and
included an evaluation of the volume of lysis buffer needed, the length and temperatures
of the incubation steps, and the addition of additional reagents such as DTT (data not
shown). The most efficient cell lysis (for both sperm and epithelial cells) was obtained
when the manufacturer’s lysis protocol was utilized except for the addition of 0.39M
DTT (data not shown).
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Evaluation of the Developed Direct Lysis Strategy

Once the laser capture micro-dissection conditions and the lysis protocol had been
optimized, the optimized conditions were evaluated by amplification of a range of sperm
cells at various amplification cycles (Table 12). One, five, and ten to one hundred sperm
cells (in ten cell increments) were collected using the Leica LMD system and lysed using
the optimized Quick ExtractTM lysis method. The 10μl lysates were then amplified using
the Profiler Plus® amplification kit (25μl reaction, 5U High Fidelity polymerase). Various
amplification cycle numbers were tested including 28 (standard), 32, 34 and 36. RFU
thresholds of 50, 100, and 150 were used to provide an indication of the signal intensities
of the recovered alleles. The number of alleles recovered (out of a possible 20 – 9 STRs
and AMEL) were recorded (Table 12). Using 28 amplification cycles, 100 or more sperm
cells were needed before a full STR profile could consistently be obtained. Even with this
number of cells, the signal intensity of many alleles was quite poor and often below 150
RFUs (Table 12). The use of four additional cycles (32 cycles) above the standard 28
cycles resulted in the need for 80-90 sperm cells for consistent profiles to be recovered
(Table 12). The use of six additional cycles (34 cycles) above the standard 28 cycles
resulted in the need for only 40-50 sperm cells for consistent profiles (Table 12). When
eight additional cycles (36 cycles) were used, as few as five to ten sperm cells were
required for minimal quality profiles (Figure 51A, Table 12). A minimal quality profile
demonstrates typical low template sample problems including peak imbalance and allele
drop-out. Ninety sperm cells were needed for a higher quality profile using 36
97

amplification cycles (Figure 51B, Table 12). With this number of cells, peak imbalance
was improved and fewer allele drop-ins were observed. As can be seen from Table 12 in
the early stages of the project a significant amount of allele drop-in was observed. As the
project progressed, the number of allele drop-ins was significant reduced. As a result, the
use of 5U of High Fidelity polymerase and 36 amplification cycles for use with STR
amplifications was determined to be optimal.

Analysis of Single Source Low Template Samples

Single source epithelial (buccal and vaginal) and sperm cells were tested to
further evaluate the optimized method involving the use of the Leica LMD system and
the Quick ExtractTM lysis method. Various numbers of sperm cells had been examined
during the test of the optimized conditions and the number of cells needed for minimal
and optimal quality profiles determined (Table 12). Therefore, single source epithelial
cell samples were analyzed using the optimized amplification conditions (36 cycles, 5U
High Fidelity polymerase). One to ten epithelial cells were collected and lysed with the
Quick ExtractTM lysis solution. Two to five epithelial cells were needed in order to obtain
minimal quality profiles (data not shown). Full autosomal STR profiles were recovered
from a single buccal (Figure 52A) and a single vaginal (Figure 52B) epithelial cell.
However, there was only partial success with profile recovery from single epithelial cells
(2/5 or 40%).
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The previous experiments had involved the collection of full epithelial cells for
analysis. Since a direct lysis strategy was developed, proteins and other cell debris are
present in the lysate. Additional purification steps could not be incorporated prior to
amplification due to the potential to lose the small amount of genetic material that was
present with sample manipulations and purification steps. An advantage of the Leica
LMD system was that it provided ability to isolate and collect small regions of interest,
allowing for portions of epithelial cells to be collected rather than whole cells. For these
studies, recovery of DNA from the micro-dissected cells was of particular interest and
therefore only the cell nucleus would be required. It was thought that if only cell nuclei
were collected, the amount of unwanted protein and cellular debris could be reduced
allowing for a possible improvement in the efficiency of profile recovery from the microdissected cells. Nucleus-only portions of epithelial cells were collected to determine if
full autosomal STR profiles would be obtained. Full autosomal profiles could be obtained
from as few as 10 nuclei (data not shown). However, there was not a significant
improvement in allelic signal or the number of cells required for a full profile compared
to whole cell collections (data not shown).

Analysis of Non-distinguishable Cell Type Mixtures

An advantage of using laser capture micro-dissection techniques is the ability to
isolate individual cells. This could be advantageous if a mixture is present, providing the
ability to isolate individual contributors. However, in some samples the presence of a
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mixture may not be visibly apparent due to the presence of non-distinguishable cell types.
In these instances, cells from multiple donors would be collected. It was therefore
necessary to ensure that the Leica-Quick ExtractTM method and the optimized
amplification conditions could accommodate mixture samples and result in the recovery
of two STR profiles.
The first type of non-distinguishable cell type mixture that was examined was
sperm-sperm cell mixtures. The sperm-sperm mixture was artificially created by
combining two semen samples in a 1:1 ratio. Various numbers of sperm cells were then
collected ranging from 5 to 100 cells (Table 13). The samples were amplified with
Profiler Plus® (5U of High Fidelity polymerase, 36 amplification). As few as thirty cells
were required in order to obtain two full autosomal STR profiles from both male
contributors (Table 13). Significant partial profiles were recovered when fewer than thirty
cells were collected.
The next type of mixture that was examined was epithelial cell mixtures. Vaginal
(female) and buccal (male) epithelial cells were mixed in a 1:1 ratio and various numbers
of epithelial cells were collected, ranging from five to thirty cells (Table 14). The samples
were amplified with the COFiler® PCR Amplification kit (5U of High Fidelity
polymerase, 36 amplification cycles). Partial and full profiles were observed for one
contributor when five to ten cells were collected (Table 14). Two full autosomal profiles
were consistently observed when twenty epithelial cells were collected (Table 14).
These results indicate that the developed lysis and amplification strategy to would
be able to provide an indication of the presence of a mixture and to recover a genetic
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profile from multiple donors. It was interesting to note that an expect number of cells
were needed to recover full profiles from both donors than would have been expected.
For example, it was determined that five to ten sperm cells and two to five epithelial cells
from single source slides were needed to obtain acceptable STR profiles. Therefore, it
would be expected that full two STR profiles would be recovered from 10-20 sperm cells
and 4-10 epithelial cells in a two-donor 1:1 mixture. Thirty sperm cells and 20 epithelial
cells were necessary to consistently obtained full profiles from both donors. It is possible
however that, even though the mixture was created in a 1:1 ratio, unequal amounts of
cells were collected from both donors. This is particular evident in the epithelial cell
mixture results (Table 14). Three 10-cell collections were analyzed and differing number
of male alleles were recovered. It is therefore possible that fewer and differing numbers
of male cells were collected in each sample, thus resulting in the failure to recover
complete profiles. For example, in the second 10-cell collection 8/14 male and 14/14
female alleles were recovered. It is possible that as few as 2 male cells could have been
collected in comparison to 8 female cells and this accounting for the difference in the
number of alleles obtained.

Analysis of Mock Casework Samples

The previous samples examined involved single source samples and artificially
created mixture samples. Additional studies were conducted that included mock
casework samples. These samples included vaginal post coital swabs (distinguishable cell
101

type mixtures), a semen stained t-shirt that had been stored at room temperature for 3.5
years, a semen sample from a vasectomized male, a menstrual blood swab and a used
beverage container lid. The results of these experiments involving mock casework
samples demonstrate the potential future application of the optimized Leica-Quick
ExtractTM method and optimized amplification strategy (36 cycles, 5U High Fidelity
polymerase) to the tools available to operational forensic crime laboratories.

3.5 Year Old Semen-Stained T-Shirt
A small portion of the semen-stained t-shirt that had been stored at room
temperature for 3.5 years was collected. When the cell suspension from this sample was
examined, a large number of cells still adhering to fibers from the t-shirt were observed
(data not shown). Several sperm cells were located detached from fibers and were
collected for analysis. A full autosomal STR profile was recovered from 15 sperm cells
collected from the 3.5 year old semen stained t-shirt with no loss of the larger alleles as is
expected with degraded DNA (data not shown).

Semen Sample from a Vasectomized Male
While it is expected that no sperm would be present in a semen sample from a
vasectomized male, it was thought that a small number of epithelial cells from the male
reproductive tract may be present. A semen sample from a vasectomized male was
102

obtained and examined for the presence of epithelial cells. A small number of epithelial
cells were observed. A single epithelial cell was collected, lysed using the Quick
ExtractTM lysis method, and amplified using the COFiler® Amplification kit (5U High
Fidelity polymerase, 36 amplification cycles). A picture of the actual cell collected for
analysis is provided in Figure 53 (bottom left). A full autosomal profile was recovered
from the single epithelial cell (Figure 53). Despite the presence of a full profile,
significant peak imbalance could be observed particularly at the TH01, CFS1PO and
amelogenin loci.

Beverage Container Lid
A beverage container lid that had been used by a male participant was swabbed
and a small number of epithelial cells were recovered, lysed using the Quick ExtractTM
method and amplified (5U High Fidelity polymerase, 36 amplification cycles). Analysis
of two (Figure 54A) and three (Figure 54B) epithelial cells from the beverage container
lid resulted in the recovery of an STR profile with only one allele drop-out and a full STR
profile, respectively.

Menstrual Blood Swab
Blood samples had previously not been included in any studies conducted as it
was difficult to recover in tact cells from a blood cell suspension. A menstrual blood
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swab was examined since it was possible that a larger number of epithelial cells might be
present. A three cell sample from the menstrual blood swab resulted in almost a complete
STR profile, with only one allele drop out at the vWA locus (Figure 55A). A five cell
sample from the same menstrual blood swab resulted in the recovery of a full STR profile
(Figure 55B). There were several alleles present not originating from the donor in the
study. While this sample was not examined for the presence of semen, the possibility that
these alleles originated from possible trace amounts of semen cannot be eliminated.

Cervico-Vaginal Post Coital Swabs
The final mock casework samples that were examined with vaginal post coital
swabs collected 12 and 36 hours after intercourse. Laser capture micro-dissection has
been suggested as a differential extraction tool, separating sperm and non-sperm fractions
prior to analysis. However, as described previously, often sperm cells are found adhering
to epithelial cells and cannot be separated if they are close or on top of the epithelial cell
nucleus. Attempts were made to locate and collect sperm cells not fully adhering to
epithelial cells. However, due to the overwhelming amount of vaginal material present on
the slide, isolated sperm cells were not frequently observed. A full autosomal STR profile
was recovered from twenty-five sperm cells collected from the 12 hour sample, with no
alleles recovered from the female donor in the study (data not shown). Since a larger
number of sperm cells were present in this sample, sperm cells not adhering to epithelial
cells were located and collected. However, fewer sperm cells were present in the 36 hour
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sample. A full male and female donor autosomal STR profile was recovered from the
analysis of twenty-five sperm cells collected from the 36-hour sample. This data indicates
the potential advantage of the use of laser capture micro-dissection in the analysis of low
template samples, but not necessarily as a replacement for a differential extraction as has
been previously suggested.

Evaluation of Whole Genome Amplification (WGA) Strategies

An evaluation of existing whole genome amplification methods was performed in
order to determine if their application to low template samples would result in the ability
to recover full STR profiles from a smaller input DNA amounts. This survey of existing
whole genome amplification methods resulted in the development of the modified
improved primer extension pre-amplification (mIPEP) method [90]. A basic diagram of
the primer extension pre-amplification is provided in Figure 56. Random 15-mer primers
hybridize through the genome and extension from these primers occurs during a larger
number of low-stringency (low annealing temperature) amplification cycles. The
developed mIPEP strategy is a modified version of and improved PEP method (IPEP). It
differs from the IPEP method in several ways: 1) it utilizes a different mixture of
polymerases – Taq polymerase (“processive”) and Tgo polymerase (“proofreading”),
contained in the Expand High Fidelity polymerase (Roche Applied Science); 2) it utilizes
significantly increased concentrations of the High Fidelity polymerase and primers; 3)
removes an additional elongation step during the amplification process; 4) eliminates the
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addition of gelatin to the amplification mix. These modifications resulted in the ability of
the mIPEP method to successfully recover full STR profiles with as little as 5pg of input
DNA, recover profiles from environmentally compromised blood samples, and from
single dermal ridge fingerprints [90]. However all of the samples used in the initial
development of this method were samples extracted using a standard organic extraction,
allowing for removal of cell debris and proteins. The mIPEP method needed to be
evaluated with micro-dissected cells in order to determine if additional modifications to
the reaction components or amplification conditions would need to be made in order to
accommodate micro-dissected cell lysates.
Initially, ten microliter cell-lysates were used directly in a mIPEP amplification
using original conditions [90]. In order to evaluate the efficiency of the mIPEP
amplification method, the mIPEP products were quantitated using the Quantifiler®
Human Real-time PCR quantitation kit. Quantitation of sperm (Figure 57A) and
epithelial cells (Figure 57B) indicate that amplification of unstained cells results in the
highest fold increase after mIPEP amplification. For sperm cells, smaller numbers of
unstained cells resulted in higher fold increases (Figure 57A). For epithelial cells, larger
fold increases were observed with larger numbers of cells (Figure 57B). For both
epithelial and sperm cells, the use of the Christmas tree stain resulted in little to no fold
increase. As a result of this study, unstained and H&E stained cells were used in
subsequent testing.
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Analysis of Micro-dissected Cells with Prior mIPEP Amplification

Single Source Samples
An advantage of the use of prior whole genome amplification is that sufficient
amounts of sample are produced that may permit the use of standard amplification
conditions in subsequent STR amplifications. The use of the Quick ExtractTM buffer
resulted in the inability to use Taq Gold polymerase in STR amplifications. In order to
determine if standard conditions could be used after prior mIPEP amplification, aliquots
of the mIPEP products were amplified with STR amplification kits using standard
amplification cycle numbers and standard amounts of Taq Gold. It was determined that
for the Profiler Plus® and COFiler® amplification kits, two times the amount of Taq Gold
could be used in order to obtain greater sensitivity (data not shown).
Ten buccal epithelial cells were lysed and amplified with mIPEP. The mIPEP
products were quantitated and 155pg of the mIPEP product was used for amplification
with both COFiler® (Figure 58A) and Profiler Plus® (Figure 58B). Full STR profiles were
recovered using both multiplex systems. There appeared to be an improvement in peak
height balance at heterozygous loci using prior mIPEP amplification for most loci, with
the exception of the D16 locus in the COFiler® profile (Figure 58). Additional STR
multiplex systems, including Identifiler® (15 locus multiplex system), MinifilerTM
(reduced sized amplicons), and Yfiler® (Y chromosome STR multiplex), were also
evaluated for use with the mIPEP amplification products. Each of these multiplex
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systems was previously tested with the non-WGA strategy and each failed to result in the
recovery of profiles from either sperm or epithelial cells. Since these multiplex systems
are more frequently being used in forensic casework, they were re-evaluated with the
mIPEP products in order to determine if profiles could be recovered from micro-dissected
cells. A partial profile recovered from 5 epithelial cells using the IdentifilerTM
amplification kit is shown in Figure 59. A genotype was not recovered at two loci (D13
and FGA) and one allele at the heterozygous D3 locus was also not recovered. However,
the partial profile that was recovered was a significant improvement compared to the
complete failure to recovery any genetic information from the non-mIPEP amplified
micro-dissected cells. With more loci contained in this single multiplex system than
Profiler Plus® or COFiler®, the partial profile recovered with the IdentifilerTM multiplex
may still result in a higher discrimination than a complete profile with either of the
smaller multiplexes. A full profile was also obtained from 10 micro-dissected epithelial
cells pre-amplified with mIPEP using the MinifilerTM multiplex system (Figure 60). This
multiplex contains reduced sized amplicons to be more suitable for use with degraded or
low template samples. However, frequently only limited partial profiles were obtained.
In addition to the numerous autosomal STR multiplex systems available, a Ychromosome STR multiplex (Yfiler®) that specifically targets male DNA, is also
available. Figure 61 shows a Y-STR profile recovered from 10 mIPEP-amplified microdissected epithelial cells, with only one locus not recovered (DYS392). This multiplex
system could be advantageous for use with low template samples since Y-STR loci are
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hemizygous in nature and would therefore eliminate potential interpretation difficulties
due to peak imbalances.
In additional to epithelial cells, micro-dissected sperm cells were also evaluated
using mIPEP pre-amplification. Figure 62 shows two autosomal STR profiles recovered
from 10 mIPEP-amplified micro-dissected cells. Ninety-eight picograms of the mIPEP
product were used to recover nearly complete COFiler® (Figure 62A) and Profiler Plus®
(Figure 62B) profiles. Allele drop-out at the D7 locus was observed in the Profiler Plus®
profile and a complete locus drop-out of the D7 locus in the COFiler® profile was also
observed (Figure 62). For a majority of the mIPEP pre-amplified samples, allele or locus
drop-out at the D7 locus was observed. A nearly complete Yfiler® profile, with one locus
drop-out at DYS392, was obtained from 15 mIPEP-amplified micro-dissected sperm cells
(Figure 63).
The results of the single source samples indicated that the use of prior mIPEP
amplification would not result in the ability to recover STR profiles from smaller
numbers of cells. However, it did result in improved sensitivity in that STR profiles could
be recovered from the same number of cells using standard conditions (28 amplification
cycles, Taq Gold polymerase) rather than increased cycle number (36 cycles) and an
alternative polymerase. These are the conditions currently used in operational crime
laboratories, thus allowing for an easier incorporation of the developed strategies into
casework without additional validation.

109

Mock Casework Samples
Additional studies were conducted to evaluate the use of prior mIPEP
amplification of mock casework samples, including a semen stained t-shirt that had been
stored at room temperature for 40 months, a used beverage container lid, and vaginal post
coital swabs. Fifteen sperm cells were collected from the 40 month old semen stained tshirt and were amplified with mIPEP. One nanogram of the mIPEP product was
amplified with Profiler Plus® (28 amplification cycles, 5U Taq Gold polymerase) and a
full STR profile was obtained (Figure 64). Ten epithelial cells were collected from a
beverage container lid that had been used by a female participant and amplified with
mIPEP. Four picograms of the mIPEP product was amplified with Profiler Plus® (28
amplification cycles, 5U Taq Gold polymerase) and a full STR profile was obtained (data
not shown). Ten and fifteen sperm cells were collected from a 24 hour post coital swab
and amplified with mIPEP. Aliquots of the mIPEP product (~860pg and ~2.1ng,
respectively) were amplified with Profiler Plus® (28 amplification cycles, 5U Taq Gold
polymerase). A partial profile was recovered from the 10 sperm cell sample (data not
shown) with a failure to recover an allele at the D18 locus and both alleles at the D7
locus. A nearly full profile was recovered from the 15 sperm cell sample (data not shown)
with only one allele not recovered at the D7 locus.
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Reproducibility Studies

Multiple amplifications of the same low template sample can be performed in
order to determine if an artifact is consistently observed or is due to stochastic effects.
However, often there is in sufficient quantities of low template samples to permit
multiple amplifications. When a direct lysis approach is used for a small number of
micro-dissected cells, the entire lysate is used in a single amplification reaction and
therefore could not be amplified more than once. A potential advantage of the use of
whole genome amplification methods for low template samples is that sufficient amounts
of the sample are produced allowing for multiple amplifications with the same
amplification kit or with several different amplification kits.
In order to evaluate the reproducibility of profiles obtained from mIPEP
amplification products two sets of experiments were conducted. The first was to collect
multiple samples containing the same number of cells (10 epithelial and 25 sperm cells)
from single source samples. These samples were amplified in separate mIPEP
amplifications and similar quantities of mIPEP product were amplified in subsequent
STR amplifications to ensure that relatively consistent profiles would be recovered. The
profiles recovered from these separate mIPEP amplifications were relatively consistent
(data not shown). However, some differences in peak balance and allele drop-out were
observed between samples due to the low-template nature of the original sample (data not
shown).
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The second type of experiment was to perform multiple amplifications from the
same mIPEP product to ensure that consistent profiles would be obtained. The multiple
amplifications included the use of the same multiplex system multiple times or different
multiplex systems. An example of multiple amplifications from the same mIPEP product
(two aliquots of the same mIPEP product from 25 sperm cells amplified in separate
Profiler Plus® reactions) can be seen in Figure 65. As can be seen from these profiles, two
full profiles were obtained with relatively similar allelic signal intensities and imbalances.
An example of multiple amplifications from the same mIPEP product using different
multiplex systems can be seen in Figure 66. The use of these two multiplex systems
allowed for additional genetic material to be recovered than if a single multiplex system
was used and also allows for a comparison of the genotypes recovered at two loci, D3
and D7, since they are contained in both systems. The same allele was not recovered at
the D7 locus in both systems indicating a possible failure to pre-amplify this allele during
the mIPEP amplification (Figure 66).

Development of Novel Y-STR Multiplex Systems

While the developed lysis and amplification strategies allowed for a greater
sensitivity and reproducibility than other low template sample analysis methods,
difficulties in profile interpretations still arose, including allele drop out and peak
imbalance. As mentioned previously, Y-chromosome STRs are hemizygous in nature
with only one allele present at most loci. Therefore, an allele drop out would result in
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failure to recover a genotype at a particular locus rather than give the appearance of a
false homozygous genotype as would be the case with autosomal STR loci.

Peak

imbalances are heterozygous autosomal STR loci can often incorrectly indicate the
presence of a mixture, with the less intense allele attributed to a minor component. If
multiple alleles are present at an individual Y-STR locus, this would more clearly
indicate the number of male donors present in the sample.
While there are significant advantages to using Y-STRs for low template sample
analysis, Y-STRs do not afford the same degree of discrimination as compared to
autosomal STRs. Most of the Y chromosome is inherited paternally as a block of linked
haplotype markers from generation to generation. Therefore, Y-STR loci are not inherited
independently and the individual discriminatory potential of each locus cannot be
combined using the product rule in order to achieve a high level of discrimination. The
frequency of a Y-STR profile therefore can only be determined through the use of the
counting method (i.e. how many times a particular profile is observed in a database). The
discrimination potential of Y-STRs is therefore limited by the size of the database and the
number of included loci.
Initially, a set of nine loci (“minimal haplotype” or MHL) were suggested for use
in forensic casework [108]. Subsequently, the MHL set was expanded to include three
additional loci in an attempt to improve discriminatory potential [109]. This set of twelve
Y-STR loci, known as the SWGDAM “core” loci have been incorporated into
commercially available Y-STR multiplexes (Promega’s PowerPlex® Y and Applied
Biosystems’ AmpFlSTR® Yfiler®) and are currently being used in forensic casework.
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However, coincidental matches between unrelated males still occur using these multiplex
systems. Therefore, there was still a need to develop new multiplex systems that could
assist in the resolution of coincidental Y-STR matches between unrelated males.
While the commercially available Y-STR multiplexes incorporate 12-17 loci, over
400 loci have been identified on the human Y chromosome with most of these loci not
well characterized [110,111]. Therefore, it is possible that more highly discriminating
loci exist than those that are currently being used. In order to begin a more systematic
analysis of novel Y-STR loci, a comprehensive STR physical map of the human Y
chromosome was created which sequentially positioned the over 400 loci along the Y
chromosome (Figure 67) [110]. Through the developed physical map, numerous
duplicate loci were identified (i.e. sequences that had been deposited into the Human
Genome Database multiple times with different DYS designations). This information was
particularly useful when attempting to design novel Y-STR multiplexes to avoid the
inclusion of duplicated loci.
An extensive evaluation of approximately 33% of all known Y-STR loci (133
loci) was performed in order to identify novel highly discriminating loci. Each locus was
evaluated based on its amplification efficiency, ability to be included into a multiplex
system, and its discriminatory potential. Numerous loci were rejected due to poor
amplification efficiencies or due to poor diversity values. The remaining loci were
incorporated into novel multiplex systems (MPIII – MPIX) in order to evaluate the
suitability of use of these multiplexes with forensic samples [96-99]. The diversity values
of each of the incorporated loci was determined and is provided in Figure 68, with the
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loci ranked from highest to lowest discrimination potential within each multiplex system.
It was apparent from this data that each multiplex system contained loci with diverse
ranges of discriminatory potential with several loci in each system with very poor
discriminatory potential. It is unlikely that operational crime laboratories would utilize all
eight multiplex systems for the analysis of individual samples due to budgetary
limitations and due to the limited quantity of genetic material often recovered from
forensic samples. Therefore attempts were made to incorporate a sub-set of the highly
discriminating loci into a single multiplex system, an ultra-high discrimination (UHD)
multiplex. The purpose of this multiplex was not to replace the currently used
commercially available multiplexes, but to improve the significance of Y-STR data in
forensic investigations. As a result, any locus selected for inclusion into the UHD
multiplex needed to be highly discriminating on its own but also demonstrate the ability
to increase the discriminatory potential of the SWGDAM core loci.
In order to determine which of the highly discriminating loci would provide the
highest support to the SWGDAM core loci, the potential increase in haplotype diversity
of the SWGDAM loci with the additional of one highly discriminating locus was
determined [100]. The increase in haplotype diversity for each locus was plotted against
its individual diversity values (Figure 69). For some loci, only diversity values from a
limited data set (n=100) were available. Therefore these loci were not immediately
considered for inclusion into UHD multiplex but were analyzed for future use. For the
remaining loci, those that were located in the upper right quadrant of the graph (high
diversity value and larger increase in haplotype diversity for the SWGDAM core loci)
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were identified as potential candidates for inclusion into the UHD multiplex. The
resulting UHD multiplex included 14 highly discriminating loci (Figure 70) and had an
overall discriminatory potential of 99.7% [100]. When the UHD multiplex was used in
addition to the Applied Biosystems’ AmpFlSTR® Yfiler® kit, 100% discrimination of all
individuals within the sample set was achieved [100]. This level of discrimination has not
been achieved with any other Y-STR multiplex system. Through the application of the
mIPEP strategy to low template samples, sufficient amounts of genetic material could be
obtained from low template samples to permit the recovery of both autosomal and Ychromosome STR data from an individual sample. This combined data could result in an
improvement in the amount of genetic data obtain (i.e. discriminatory potential) but could
also result in an improvement in the interpretation of challenging low template samples.
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CHAPTER SIX: DISCUSSION
In this report we have demonstrated the ability to obtain standard and novel
genetic information from low template samples, including a determination of the time
since deposition of dried bloodstains using spectrophotometric analysis of hemoglobin
and a progressive decline in enzyme activity, an identification of the body fluid of origin
using miRNA profiling, and a determination of the genetic profile of the donor of a small
number of micro-dissected cells using standard and novel DNA biomarkers. Collectively
these findings constitute the basis for the development of a “genetic eyewitness” profiling
system for low template biological samples.
Hemoglobin UV-Visible spectrophotometric profiles were successfully obtained
from dried bloodstains. Upon examination of the characteristic peaks in the visible
absorption spectral data from aged bloodstains, a hypsochromic shift (shift to shorter
wavelength) of the Soret band was observed as the age of the stain increased. A
significant correlation between the age of the stain and the ΔλSoret (hypsochromic shift)
was demonstrated (R2 > 0.9 in most cases). The hypsochromic shift measurements
resulted in the highest resolution of any previously developed TSD method enabling
bloodstains differing in age by minutes, days, weeks and months to be distinguished.
Additionally, it was demonstrated that determined that hypsochromic shift measurements
could be obtained from sub-microliter quantities of blood from stains as small as 1 μl. To
our knowledge, this is the first strategy that permits the determination of the time since
deposition of low template samples with this level of sensitivity. The potential to perform
this analysis “on-site” at crime scenes was also demonstrated through the use of a
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portable “point-of-use” spectrophotometer allowing crime scene technicians to identify
the presence of a bloodstain (through a characteristic UV-VIS spectral profile) and also
determine the time since deposition of that bloodstain. This information, therefore, could
immediately provide investigators with a molecular estimation of when a crime occurred
and could assist in the determination of what evidence to collect for further analysis.
While the hypsochromic shift assay permitted a determination of the time since
deposition of bloodstains, the molecular basis for the shift is theorized to be the result of
oxidation to the central Fe2+ ion in heme. If this hypothesis is correct, there are numerous
environmental factors that could influence the rate of oxidation and therefore affect the
accuracy of the time since deposition measurements. It was determined that the rate and
extent of the hypsochromic shift was increased at higher temperatures and reduced at
higher humidity levels. Despite the changes in the rate of the shift, the correlation
between the hypsochromic shift and the age of the stain was still significant. Therefore
with prior knowledge of a reasonable estimate of storage conditions, it may be possible to
still obtain accurate estimations of the time since deposition. For samples exposed to
relatively constant temperatures and humidity levels that could be more accurately
measured (i.e. indoor environments), reference curves established from samples stored at
similar conditions could be used to determine the time since deposition. However, it is
more difficult to perform such an analysis or obtain reference samples for samples found
in variable environments (i.e. outdoor environments). In outdoor settings, there are
fluxuations in temperature, humidity and level of precipitation that may not be easily
recorded. During our analysis of bloodstains that had been stored outside, we had to rely
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on reported high and low temperatures and humidity levels since it was not possible to
continuously monitor environmental changes. Upon comparison of the hypsochromic
shift to reference samples closest to the approximated temperature, it was determined that
the samples had been likely exposed to much higher temperatures than previously
thought. This data, therefore, reflects the danger in relying on reported environmental
conditions and indicates a necessity for constant monitoring of environmental conditions
before time since deposition determinations can be made. This would not be feasible or
practical with the current capabilities of and demands on operational forensic
laboratories. However, these challenges represent technological obstacles and are not
indicative of a failure of the developed strategy. If proper methods for the determination
of the precise environmental conditions to which a sample was exposed can be
developed, then accurate estimations of the time since deposition could be made.
Despite the ability of the hypsochromic shift to provide high resolution
determinations of the time since deposition, it is limited to the analysis of bloodstains.
Since other biological fluids are frequently encountered in forensic investigations,
additional strategies needed to be developed to allow for a determination of the time since
deposition of other forensically relevant fluids. We hypothesized that it could be possible
to identify fluid-specific enzyme candidates and that the progressive loss of activity of
the enzymes could provide an indication of the time since deposition of biological fluids.
We successfully demonstrated that enzyme activity could be detected in dried
bloodstains. A linear correlation between the age of the stain and the loss of enzyme
activity was observed for six enzyme candidates (lactate dehydrogenase, malate
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dehydrogenase, alcohol dehydrogenase, isocitrate dehydrogenase, phosphogluconate
dehydrogenase, and glycerate dehydrogenase). While month differences in stain age were
needed, the resolution of this method could be improved with the identification of
additional enzyme candidates. While only bloodstains were used in initial testing as a
proof-of concept, our findings support the potential future use of enzyme activity changes
for the determination of the time since deposition of other forensically relevant biological
fluids as well.
Currently, the methods routinely used in forensic casework for the identification
of biological fluids in evidentiary items are costly in terms of time and sample and have
varying degrees of sensitivity and specificity. Recently the use of molecular based body
fluid identification methods, such as messenger RNA (mRNA) profiling based on tissuespecific gene expression, has been proposed to supplant conventional methods for body
fluid identification [8-10,112-114]. While the advantages of mRNA profiling compared
to conventional methods include greater specificity, improved timeliness, and the ability
to perform simultaneous and semi-automatic analyses, the size of the amplification
products used in these assays (~200-300 nt) and the significant amount of input RNA
required for analysis (~50 ng) may not make this method well-suited for the analysis of
low template forensic specimens. Recently, there has been increased scrutiny of a newly
identified class of small non-coding RNAs, microRNAs (~20-25 nt in length) with
numerous published studies reporting an identification of potential tissue-specific
candidates. In this report, we demonstrated that miRNAs are present in total RNA
isolates from body fluid stains in sufficient quantity for analysis and also provided the
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first comprehensive evaluation of miRNA expression in forensically relevant biological
fluids (blood, semen, saliva, vaginal secretions and menstrual blood) in an attempt to
identify potentially body-fluid specific miRNAs. While no truly fluid-specific candidates
were identified (in the sense of being present in one body fluid but completely absent in
the others), we developed a panel of 9 differentially expressed miRNAs for the
identification of the body fluid origin of biological stains. The normalized expression of
each of the miRNA pairs exhibited a body fluid-specific expression pattern which
allowed for an identification of the body fluid of interest.
The miRNA body fluid identification assays successfully detected the presence of
biological material in aged and environmentally compromised samples as well as in
simulated casework samples that included admixed body fluid samples, post coital
samples and trace body fluid samples. While the results of this study support the potential
future use of the miRNA profiling assays to identify the body fluid origin of forensic
biological samples, it is recognized that additional work is needed prior to the utilization
of miRNA profiling in forensic casework. Additional miRNA candidates for use in the
body fluid identification assays need to be identified. From our initial screen of the 452
miRNAs, only a single strong candidate was identified for vaginal secretions and
menstrual blood and no strong candidates for semen were identified. While the candidate
used in the assays for each of these fluids still provide the ability to distinguish the body
fluid of interest, the inclusion of stronger candidates would only serve to enhance our
ability to do so. Since the initial evaluation of the 452 miRNAs, an additional ~300
miRNAs have been added to the miRNA database [115] and it is possible that better
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candidates for each body fluid may be identified through an evaluation of these new
miRNAs.
Due to the significantly smaller size of miRNAs compared to mRNAs, we
hypothesized that miRNAs may be less susceptible to degradative processes (i.e. RNase
digestion) and therefore more stable in aged, degraded or environmentally compromised
samples. In order to test this hypothesis, total RNA extracts degraded with various RNase
enzymes would need to be assessed using both miRNA and miRNA profiling assays in
order to determine if stability differences can be observed. In additional to an evaluation
of the stability differences between the difference classes of RNAs, a comprehensive
evaluation of all currently available body fluid identification methods (serological,
immunological, mRNA profiling, and miRNA profiling) would need to be conducted on
compromised biological stains in order to fully determine the most suitable approach to
body fluid identification of forensic specimens.
A positive body fluid identification using our current miRNA body fluid
identification assays is determined by the proximity of the unknown sample to the cluster
of known human biological samples. Typically an elliptical boundary was defined around
the known body fluid sample clusters. Using this type of simplified approach, in some
cases subjective calls for weakly positive samples needed to be made. In order to provide
a robust objective approach for declaring the presence of a particular body fluid, more
refined analysis interpretation metrics such as those based upon discriminant function
analyses [116] will need to be developed.
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The development of powerful and robust DNA typing strategies (STR analysis)
has made it is possible to ascertain with a high degree of certainty whether a biological
stain found at a crime scene originated from a particular individual. However, the
standard profiling methods typically will fail to recover suitable genetic profiles from low
template samples which contain less than 100 pg of template DNA (equivalent to
approximately 15 diploid or 30 haploid cells). If profiles are recovered from these
samples, interpretation is often difficult due to the occurrence of allelic drop-out or dropin and significant peak height imbalance. The frequency of low template samples and the
difficulty of interpretation warrant development of additional methodologies to allow for
more successful recovery of genetic information. We have developed a “smart” low
template sample analysis approach that utilizes laser capture micro-dissection to recover
individual and few cells and enhanced amplification strategies to recover full autosomal
and Y chromosome STR profiles from 2-5 epithelial cells and 5-10 sperm cells from
single and multiple donor samples.
We had anticipated that the use of prior whole genome amplification strategies
would allow for the recovery of genetic profiles from a smaller number of cells.
However, surprisingly, an increase in sensitivity was not observed. Despite the inability
to recover profiles from smaller numbers of cells, several advantages to prior whole
genome amplification were observed. To obtain the high level of sensitivity without
WGA methods, modified strategies were employed that are not currently utilized by
operational crime laboratories. The use of the mIPEP amplification method allowed for
subsequent use of standard conditions for downstream typing assays eliminating the need
123

for additional extensive validations of new methodologies. Without prior WGA
amplification, micro-dissected cell lysates could only be used in a single STR
amplification reaction thereby limiting the amount of genetic information that could be
obtained. Sufficient quantities of template DNA was produced with prior mIPEP
amplification to allow for aliquots of the same sample to be analyzed with multiple STR
systems. This not only allowed for the recovery of an extended DNA profile (autosomal
STRs, Y chromosome STRs), but also allowed for the reproducibility of the profile to be
assessed through repeated amplifications. There is an occasional overlap between the loci
included in the various multiplex systems and the concordance of genotypes recovered at
these loci could therefore be established. Additionally, significant peak imbalance and
allele drop in are observed and could incorrectly indicate the presence of a mixture. The
presence of a random allele drop in from an adventitious allele could be established
through repeated amplification of the same sample. If an additional allele at a particular
locus was not observed in each of the multiple amplifications, it would be recognized as
an artifact (allele drop-in) rather than a possible indicator of the presence of a minor
contributor. Additionally, possible differences in allelic signal intensity within a
heterozygous genotype may be observed between multiple amplifications of the same
sample. If an allele was found in lower intensity in each of the multiple amplifications
that it could suggest the presence of a minor contributor. However if each of the alleles
was observed in higher intensity, it could suggest the presence of an imbalanced
heterozygous type from a single donor. The resolution of these often challenging
interpretations would not be possible without the use of prior WGA strategies.
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Currently, there is much debate over the validity of low template sample analysis,
with skeptics criticizing the reliability of any results obtained from such samples due to
the encountered difficulties in profile interpretation [117-120]. However, rather than
viewing potential weakness in low template sample analysis as reasons for its exclusion
in forensic casework, we have viewed it as an opportunity for scientific advancement to
overcome any perceived limitations. In this work, we have demonstrated the ability to
obtain significant probative information (time since deposition, identification of the body
fluid of origin, and recovery of genetic profiles) from low template samples. Based on
our findings, we believe that, with further advancements, routine and reliable analysis of
low template samples in forensic casework will be possible, perhaps even at a true
cellular level.
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CHAPTER SEVEN: CONCLUSION
In this study, we have identified novel DNA, RNA and protein biomarkers that
allowed for the development of a “genetic eyewitness” to provide investigators with the
“who”, “what”, and “when” of criminal offenses. We have identified a novel
hypsochromic shift of the Soret band of hemoglobin spectral profiles that allows for a
determination of the time since deposition of dried bloodstains. We also demonstrate the
possibility of using a decline in enzyme activity to determine the age of biological stains.
We have developed a novel strategy for the identification of the source of biological
stains utilizing the differential expression of miRNAs. We have developed a “smart” low
template sample analysis approach that utilizes laser capture micro-dissection to recover
individual and few cells and enhanced amplification strategies to recover full autosomal
and Y chromosome STR profiles from 2-5 epithelial cells and 5-10 sperm cells.
Additionally, the development of a novel whole genome amplification method (‘modified
improved primer extension pre-amplification’ or mIPEP) to be used prior to the locus
specific PCR amplifications resulted in the ability to perform multiple amplifications of
the same micro-dissected cell sample and resulted in a greater recovery of heterozygous
genotypes at individual loci. The novel biomarkers and profiling strategies described in
this report provide the basis for the establishment of a molecular “genetic eyewitness”
from low template forensic samples. The strategies presented here not only provide more
sensitive and reliable means by which to analyze low template samples, but also provide
an indication that with continued progress it may be possible to perform routine forensic
analyses on single cells.
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APPENDIX A: FIGURES
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Figure 1. Characteristic UV-VIS Spectral Profile of Hemoglobin
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Figure 2. Changes in UV-VIS Spectral Profile of Hemoglobin in Aged Bloodstains
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Figure 3. Hemoglobin Spectral Shift Parameters
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22oC-1:
r2 = .7577
y = -0.0024Ln(x) + 0.0149

22oC-2:
r2 = .7706
y = -0.0094Ln(x) + 0.0563

37oC-1:
r2 = .7812
y = -0.0024Ln(x) + 0.0218

37oC-2:
r2 = .7109
y = -0.0097Ln(x) + 0.0691

Figure 4. ΔAbsβ(541-560) for Bloodstains Stored at 22oC and 37oC
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22oC-1:
r2 = .8564
y = -0.0027Ln(x) + 0.0132

22oC-2:
r2 = .8019
y = -0.0063Ln(x) + 0.0327

37oC-1:
r2 = .926
y = -0.0037Ln(x) + 0.0178

37oC-2:
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y = -0.0099Ln(x) + 0.0478

Figure 5. ΔAbsα(576-560) for Bloodstains Stored at 22oC and 37oC
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22oC-1:
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y = -0.121Ln(x) + 0.6836

22oC-2:
r2 = .9453
y = -0.1116Ln(x) + 0.6639

37oC-1:
r2 = .9596
y = -0.1467Ln(x) + 0.6034

37oC-2:
r2 = .9789
y = -0.1377Ln(x) + 0.7541

Figure 6. ΔAbsα(576-560)/ΔAbsβ(541-560) for Bloodstains Stored at 22oC and 37oC
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Figure 7. ΔλSoret for Bloodstains Stored at 22oC and 37oC
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Microplate:
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y = -0.4152Ln(x) + 411.87

UV spec:
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y = -0.5967Ln(x) + 413.42

Figure 8. Comparison of ΔλSoret Measurements Using Two Different
Spectrophotometers
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Figure 9. MicroClimate(R) Humidity Chamber MCH-3
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Images generated from public website: http://cdo.ncdc.noaa.gov/cgi-bin/climaps/climaps.pl

Figure 10. National Mean Relative Humidity and Mean Daily Temperature (19611990)
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75% Humidity:
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y = -0.6685Ln(x) + 413.58
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85% Humidity:
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75% Humidity:
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y = -0.994Ln(x) + 413.13

80% Humidity:
r2 = .9586
y = -0.8393Ln(x) + 413.39

85% Humidity:
r2 = .8428
y = -0.6141Ln(x) + 413.74

Figure 11. Effects of Humidity on ΔλSoret Measurements for Bloodstains Stored at
22oC and 30oC
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Figure 12. Effects of Temperature on ΔλSoret Measurements for Bloodstains Stored
at 50% Humidity
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Original:
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r2 = .9895
y = -0.7695Ln(x) + 413.19

-20oC – 2wks:
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y = -0.6064Ln(x) + 412.39

Figure 13. Effects on ΔλSoret from Length of Storage Prior to Analysis
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50% Humidity:
r2 = .9861
y = -0.7548Ln(x) + 413.05

75% Humidity:
r2 = .928
y = -0.6685Ln(x) + 413.58

80% Humidity:
r2 = .9351
y = -0.5826Ln(x) + 413.58

85% Humidity:
r2 = .8118
y = -0.2609Ln(x) + 413.69
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B

30oC
50% Humidity:
r2 = .9631
y = -0.8182Ln(x) + 412.34

75% Humidity:
r2 = .9309
y = -0.994Ln(x) + 413.13

80% Humidity:
r2 = .9586
y = -0.8393Ln(x) + 413.39

85% Humidity:
r2 = .8428
y = -0.6141Ln(x) + 413.74

Outside sample: Humidity (High-98%, Low-46%)

OSC:
r2 = .8968
y = -1.1379Ln(x) + 411.85

Figure 14. Effects of Outside Storage on ΔλSoret Measurements Compared to
Storage at 22oC and 30oC
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Figure 15. Effects of Outside Storage on ΔλSoret Measurements Compared to
Bloodstains Stored at 22oC, 30oC, and 37oC
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Figure 16. ΔλSoret Measurements from Bloodstains Located in Car Trunk
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Figure 17. Hb Spectral Profiles Using a Range of Total Protein Input Amounts
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Figure 18. Sensitivity of ΔλSoret Measurements - Total Protein Input
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Figure 19. Size of Bloodstains Used to Determine the Sensitivity of the ΔλSoret
Assay
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Figure 20. UV-VIS Spectral Profiles from 1 μl Bloodstains Using Nanoliter Input
Volumes
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Figure 21. UV-VIS Spectral Profiles from 0.5 and 0.75 μl Bloodstains
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Figure 22. Accuracy of ΔλSoret Measurements from 0.5 and 0.75 μl Bloodstains
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Figure 23. Appearance of Large and Small Bloodstains
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Figure 24. Effects of Bloodstain Size on ΔλSoret Measurements
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Figure 25. Comparison of the Accuracy of ΔλSoret Measurements Using a BenchTop and Portable Spectrophotometer
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Figure 26. Decline in Enzyme Activity in Aged Bloodstains
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Figure 27. Determination of the Differential Expression of miRNAs in Forensically
Relevant Biological Fluids

154

Figure 28. miRNA Expression Heat Map
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Figure 29. Relative Expression of miRNA Body Fluid Candidates
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Figure 30. 2D miRNA Body Fluid Identification Assays
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Figure 31. 3D Vaginal Secretion miRNA Assay
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Figure 32. Evaluation of Additional Samples with the miRNA Body Fluid Assays
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Figure 33. Tissue Specificity of the miRNA Body Fluid Assays
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Figure 34. Species Specificity of the Blood and Saliva miRNA Body Assays
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Figure 35. Improved Species Specificity of the U-44 Normalized Blood miRNA
Assay
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Figure 36. Stability of miRNA in Aged and Environmentally Compromised Body
Fluid Samples
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Figure 37. Stability of Vaginal Secretion miRNAs during the Menstrual Cycle
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Figure 38. Detection of Body Fluids in Simulated Forensic Casework Samples
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Figure 39. Detection of Blood and Semen in an Admixed Sample
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Figure 40. Detection of Semen and Saliva in an Admixed Sample
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Figure 41. Expression Profile of Menstrual Blood with the miRNA Body Fluid
Assays
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Figure 42. Specificity of the Menstrual Blood miRNA Assay
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Figure 43. Stability of the Menstrual Blood miRNA Assay during the Menstrual
Cycle
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Figure 44. Evaluation of Venous Blood -Vaginal Secretion Mixtures Using the
Menstrual Blood miRNA Assay
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Figure 45. Proposed Schema for the Analysis of Biological Evidence of Unknown
Origin using miRNA Body Fluid Profiling
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Figure 46. Challenges Associated with Low-Template Sample Analysis
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Figure 47. Single Sperm Cell Removal Using the Arcturus PixCell II System
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Figure 48. Removal of Sperm Cells Adhering to Epithelial Cells using the Arcturus
PixCell System
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Figure 49. Sperm Cell Removal using the Leica LMD System
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Figure 50. Removal of Sperm Cells Adhering to Epithelial Cells Using the Leica
LMD System
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Figure 51. Autosomal STR Profile Recovery from Micro-dissected Sperm Cells
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Figure 52. Autosomal STR Profiles Obtained From Single Micro-dissected
Epithelial Cells
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Figure 53. Autosomal STR Profile Recovered From a Single Epithelial Cell from a
Vasectomized-Male Semen Sample
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Figure 54. Autosomal STR Profiles Recovered from Epithelial Cells from Beverage
Container Lids
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Figure 55. Autosomal STR Profiles Recovered from Epithelial Cells from Menstrual
Blood Samples
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Figure 56. Basic Primer Extension Pre-Amplification Strategy
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Figure 57. Affects of Cell Staining on Amplification Yield Following mIPEP
Amplification
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Figure 58. Autosomal STR Profiles Recovered from mIPEP-Amplified Microdissected Epithelial Cells After mIPEP Amplification
185

5 cells
P

LDO
ADO
(16)

P

LDO

P

LDO = locus drop out, ADO = allele drop out, P = pull-up

Figure 59. Mega-plex Autosomal STR Profile Recovered from Micro-dissected
Epithelial Cells
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Figure 60. Mini Autosomal STR Profile Recovered from mIPEP-Amplified Microdissected Epithelial Cells
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Figure 61. Y-Chromosome STR Profile Recovered from mIPEP-Amplified Microdissected Epithelial Cells
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Figure 62. Autosomal STR Profiles Recovered from mIPEP-Amplified Microdissected Sperm Cells
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Figure 63. Y-Chromosome STR Profile Recovered from mIPEP-Amplified Microdissected Sperm Cells
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Figure 64. Autosomal STR Profile Recovered from mIPEP-Amplified Sperm Cells
Collected from a 40-Month Old Semen-Stained T-Shirt
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Figure 65. Reproducibility of Profiles Obtained from Multiple Amplifications of the
Same mIPEP Product
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Figure 66. Multiple STR System Profiles Recovered from a Single mIPEP Product
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Figure 67. STR Physical Map of the Human Y Chromosome
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Figure 68. Gene Diversity Values of Loci Contained in Novel Y-STR Multiplexes
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Figure 69. Evaluation of Individual Y-STR Locus Contribution to the Haplotype
Diversity of Commonly Used Y-STRs
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Figure 70. Ultra-High Discrimination (UHD) Y-STR Multiplex
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APPENDIX B: TABLES
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Table 1. Evaluation of the Correlation Between Age of the Stain and the Soret Band
Hypsochromic Shift Using Various Age Intervals
Sample
22oC
37oC

15min-2days
“Hours”
0.9550
0.9843

r2 value
15min-1 week
15min-1 month
“Days”
“Weeks”
0.9481
0.9566
0.9667
0.9556
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15 min-1 year
“Months”
0.9626
0.8430

Table 2. Comparison of the ΔλSoret For Bloodstains Stored at 22oC Using Two
Different Spectrophotometers
Sample
15 min
30 min
1 hour
3 hours
6 hours
18 hours
24 hours
48 hours
1 week
1 month
3 months
6 months
1 year

λSoret –
Microplate Reader
412.5
412.0
412.0
411.3
411.0
411.0
410.8
410.0
408.7
408.0
407.5
408.0
407.5
Total shift = 5nm

λSoret –
UV Spectrophotometer
414.0
414.0
413.7
413.0
411.7
412.0
411.8
411.0
410.3
409.2
408.7
408.7
406.3
Total shift = 7.7nm
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Difference
1.5
2.0
1.7
1.7
0.7
1.0
1.0
1.0
1.6
1.2
1.2
0.7
-1.2
Average = 1.1nm

Table 3. Comparison of Hypsochromic Shift Correlation Values Using Two
Different Spectrophotometers
22oC
Microplate
Reader
UV- Spec

37oC

15min-48hrs
0.9462

15min-1yr
0.9592

15min-48hrs
0.9858

15min-1yr
0.8250

0.9180

0.9577

0.9534

0.8130
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Table 4. Comparison of λSoret for Standard (60 μl) and Small Bloodstains (< 1 μl)

Full stain (60μl)
0.75 μl stain
0.5 μl stain

Average λSoret
48 hour
410.1
408.0
408.0

15 minutes
412.8
412.0
412.0
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1 week
408.9
406.0
406.0

Table 5. Enzyme Candidates For Time Since Deposition Assays

Enzyme
Lactate dehydrogenase
Malate dehydrogenase
UDPglucose dehydrogenase
Glycerate dehydrogenase
Galactose dehydrogenase
Octanol dehydrogenase
Aldehyde dehydrogenase
Fumarate hydratase
Dihydrooroate dehydrogenase
L-glutamate dehydrogenase
Isocitrate dehydrogenase
Phosphogluconate dehydrogenase
Glucose-6-phosphate
dehydrogenase
Aconitase
Phosphoglucomutase
L-xyulose reductase
Glycerol dehydrogenase
Carbonic anhydrase
Glycerol -3-phosphate
dehydrogenase
Alcohol dehydrogenase
3-Hydroxybutyrate dehydrogenase
Gluconate dehydrogenase
Guanine deaminase
Succinate dehydrogenase
Purine nucleoside phosphorylase
Aldehyde oxidase
L-amino acid oxidase
Sarcosine Oxidase
Uricase
Cytochrome-C oxidase
Cholinesterase
Acid phosphatase

Detection
NAD
NAD
NAD
NAD
NAD
NAD
NAD
NAD
NAD
NADP
NADP
NADP
NADP
NADP
NADP
NADP
NADP
4-MU
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
NBT-formazan
NBT-formazan
NBT-formazan
NBT-formazan
Indophenol blue
(vis)
Fast Red RT
Fast Blue BB
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Secondary
Detection
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan
MTT-formazan

Table 6. Time Required for Complete Loss of Enzyme Activity in Aged Bloodstains
Enzyme
Glycerate dehydrogenase
Lactate dehydrogenase
Isocitrate dehydrogenase
Alcohol dehydrogenase
Phosphogluconate dehydrogenase
Malate dehydrogenase
L-xyulose reductase
3-hydroxybutyrate dehydrogenase
Phosphoglucomutase
Glucose-6-phosphate dehydrogenase
Gluconate dehydrogenase

Months to Reach 0 Activity
10.1
11.4
11.8
14.4
16.0
20.7
28.7
144.7
Stable
Stable
Stable
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Table 7. Characteristics of miRNA Panel and Normalizers for Body Fluid Identification Assays

Sanger ID

microRNAs
Sequence

Blood
Menstrual Blood
Blood

AAACCGUUACCAUUACUGAGUU

Entrez
Gene ID
574411

UAGCAGCACGUAAAUAUUGGCG

--

MIMAT0000069

hsa-miR-135b
hsa-miR-10b

Semen
Semen

UAUGGCUUUUCAUUCCUAUGUGA
UACCCUGUAGAACCGAAUUUGUG

-406903

MIMAT0000758
MIMAT0000254

hsa-miR-658
hsa-miR-205

Saliva
Saliva

GGCGGAGGGAAGUAGGUCCGUUGGU
UCCUUCAUUCCACCGGAGUCUG

724028
--

MIMAT0003336
MIMAT0000266

hsa-miR-124a

Vaginal Secretions

UAAGGCACGCGGUGAAUGCC

--

MIMAT0000422

hsa-miR-372
hsa-miR-412

Vaginal Secretions
Menstrual Blood

hsa-miR-451
hsa-miR-16

RNU6b
SNORD44

Body Fluid
Assay

All
Blood - species

Mature sequence
Sanger Accession #

Literature
Ref.

MIMAT0001631

[55,59,61,121123]
[41,59,124,125
]
[59,126,127]
[46,48,50,57,5
9]
none
[4245,50,52,59,12
8]
[47,50,53,56,5
9,129]
[50,59,130]
none

MIMAT0000724
442917
MIMAT0002170
574433
Small non-coding RNAs (snRNA/snoRNAs) - Normalization
CTGCGCAAGGATGACACGCAAATTCGTGAA
Not applicable
26826
AAAGUGCUGCGACAUUUGAGCGU
ACUUCACCUGGUCCACUAGCCGU

GCGTTCCATATTTTT
CCTGGATGATGATAGCAAATGCTGACTGAAC
ATGAAGGTCTTAATTAGCTCTAACTGACT
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26806

Not applicable

[131-133]
[131,134]

Table 8. Determination of Negative Result Threshold Values Through Assessment of Negative Controls
RT (-) samples
Blood
Semen
Saliva
Vag.Sec
Mnstrl.Bld
Avg

miR451

miR16

miR135b

miR10b

miR658

miR205

miR124a

miR195

miR372

miR412

U6b

U6b

U44

50pg

50pg

500pg

500pg

50pg

50pg

50pg

50pg

50pg

50pg

50pg

500pg

50pg

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

40.0
40.1
41.1
40.5
42.6
40.9

40.1
39.5
39.9
40.6
40.9
40.2

37.3
37.3
37.0
37.1
37.6
37.3

45.6
46.9
45.1
46.8
Undet.
46.1

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

41.1
43.0
42.6
40.7
42.1
41.9

35.8
35.7
35.3
35.6
36.2
35.7

35.4
36.0
35.4
35.5
35.4
35.5

Undet.
Undet.
Undet.
Undet.
Undet.
Undet.

0.3

0.3

SD

N/A

N/A

N/A

N/A

1.1

0.6

0.2

0.9

N/A

1

Invalid
Result

N/A

N/A

N/A

N/A

>37.5

>38.5

>36.5

>43.0

N/A

>39.0

miR451

miR16

miR135b

miR10b

miR658

miR205

miR124a

miR195

miR372

miR412

U6b

U6b

U44

50pg

50pg

500pg

500pg

50pg

50pg

50pg

50pg

50pg

50pg

50pg

500pg

50pg

37.9
38.2
36.9

37.2

32.5
32.4
31.2
31.9

36.6

31.7

24.8
30.2
31.9
28.3
27.6

22.3
29.2
28.5
27.5
25.1

28.0
43.2
37.9
33.9
32.4

>34.5 >34.5

N/A

N/A

RT (+) samples
37.9
39.4
37.5
36.4
33.1
18.5
Blood
16.3
17.8
31.6
30.2
39.6
34.0
33.8
36.0
Semen
33.4
34.7
32.2
29.4
36.5
42.6
31.6
29.6
Saliva
27.7
27.1
34.4
32.4
40.7
39.3
33.6
29.9
VagSec
25.1
32.9
26.5
37.9
36.9
35.2
28.5
26.0
26.4
Mnstrl.Bld 24.4
Undet. = undetected (Ct > 50); N/A = not applicable; SD = standard deviation
Threshold = Average – 3 SD (rounded to nearest .5 value)
RT (-) = negative reverse transcription reaction (no reverse transcriptase enzyme added)
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Table 9. Sensitivity and Specificity of snRNAs and snoRNAs in Biological Stains

Sample
Blood
Semen
Saliva
Vaginal Secretions
Menstrual Blood
Dog
Cat
Horse
Crane
Cow
Sheep
Coyote
Pat. Cavy
Ferret
Deer
Tortoise
Lamb
Chimpanzee
Baboon
Brown Lemur
Howler monkey
Cynomolgus monkey
African Green monkey
Spider Monkey
Rhesus macaque
Pig-tailed macaque

U6b
24.8
29.2
31.9
28.3
27.6
23.7
24.6
25.1
25.9
22.4
22.9
28.5
29.7
24.4
23.8
29.6
21.5
24.3
25.0
25.2
24.3
24.3
25.1
27.6
22.8
23.8

U44
28.3
43.2
37.9
33.9
32.4
41.7
42.3
48.9
42.0
39.2
40.7
Undet.
42.4
49.2
42.5
40.2
41.5
28.7
39.5
Undet.
40.3
Undet.
48.9
48.1
43.3
Undet.

U26
27.0
43.2
34.5
30.7
28.4
44.0
42.5
41.5
48.0
39.1
38.9
49.2
Undet.
43.5
44.0
46.8
40.1
26.5
27.1
40.2
28.2
26.6
26.6
31.7
27.0
32.5

U27
27.2
39.6
34.1
30.5
28.4
28.1
36.3
38.8
38.6
25.5
26.3
33.2
40.2
29.3
31.1
40.6
26.9
25.8
26.8
27.5
28.0
26.4
28.4
31.1
27.9
27.4

U28
30.5
42.1
40.4
34.2
30.6
42.6
42.8
40.2
40.9
38.4
40.3
43.7
42.4
Undet.
40.4
42.6
40.6
30.1
31.1
30.8
31.0
30.0
30.2
34.6
30.5
30.4

Undet = undetected (Ct > 50) ; NT = not tested
207

Ct values
U29
U30
27.3
39.4
38.0
29.8
34.8
38.6
33.1
33.4
28.9
29.2
40.2
47.1
41.1
42.3
39.3
45.1
48.3
47.1
32.4
43.1
34.3
44.1
44.2
Undet.
45.3
Undet.
36.0
Undet.
37.8
45.4
47.0
41.5
33.6
39.1
31.2
29.0
32.3
44.4
33.4
43.4
32.8
43.6
30.8
44.8
31.1
40.7
36.1
43.9
32.8
44.6
36.9
47.7

U31
35.6
26.6
33.2
31.5
27.2
35.0
42.3
28.3
Undet.
40.0
27.7
39.6
40.8
35.7
31.9
42.3
27.1
26.2
26.3
27.1
27.3
27.1
26.4
28.9
25.7
26.6

U38B
33.0
41.4
38.3
36.5
32.5
38.1
40.9
41.4
41.6
39.5
41.2
42.0
47.0
40.5
42.5
35.8
37.8
NT
NT
NT
NT
NT
NT
28.8
29.2
35.7

U43
30.2
33.6
32.0
32.9
29.3
29.3
31.1
33.0
35.5
30.1
28.6
29.7
28.5
28.9
28.6
32.6
29.4
29.7
29.7
35.7
30.3
29.3
31.3
29.2
28.4
29.7

U48
32.0
40.8
38.2
36.1
30.2
38.8
39.4
39.6
42.5
39.9
39.6
42.8
44.0
41.8
Undet.
36.6
45.9
NT
NT
NT
NT
NT
NT
41.0
28.2
29.8

U90
35.3
42.3
44.1
37.8
34.4
40.4
42.5
41.5
40.0
44.0
39.7
40.1
39.3
42.2
41.4
38.1
39.3
NT
NT
NT
NT
NT
NT
41.9
39.2
39.1

Table 10. Summary of Conditions for Environmentally Compromised Samples
Outside, Covered (OC) – Exposed to heat, light and humidity
Exposure
Temperature Range
Humidity Range
o
o
Low ( F) High ( F) Minimum Maximum
Blood
3 days
66
90
44
93
7 days
66
92
44
90
1 month
66
95
43
87
Semen
3 days
66
92
45
93
7 days
66
93
45
91
1 month
66
96
44
88
Saliva
3 days
66
92
45
93
7 days
66
93
45
91
1 month
66
96
44
88
Vaginal Secretions
3 days
72
94
38
86
7 days
72
96
43
86
1 month
71
96
46
88

Rain
(inches)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

Outside, Uncovered (OUC) – Exposed to heat, light, humidity and rain
Body Fluid
Exposure
Temperature Range
Humidity Range
Low (oF) High (oF) Minimum Maximum
Blood
1 day
66
88
38
84
3 days
66
90
44
93
7 days
66
92
44
90
Semen
1 day
66
89
42
94
3 days
66
92
45
93
7 days
66
93
45
91
Saliva
1 day
66
89
42
94
3 days
66
92
45
93
7 days
66
93
45
91
Vaginal Secretions
1 day
72
90
50
84
3 days
72
91
46
85
7 days
72
96
47
88

Rain
(inches)
0.63
1.59
2.70
1.59
1.59
2.70
1.59
1.59
2.70
1.26
1.28
7.56

Body Fluid
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Table 11. miRNA Stability - Body Fluid Identification in Aged and Compromised Biological Fluid Samples

Blood assay
(451-16)

Blood

22oC

22oC

37oC

37oC

OC

OC

OC

OUC

OUC

OUC

1 year

18 months 2
years*

3 months

6 months

3 days

1 week

1 month

1 day

3 days

1 week

+

+

-

+

-

+

NA

+

+

+

+

-

+

-

-

U6b-

-

-

-

-

U6b-

-

-

-

Semen
Semen assay
(135b-10b)

+

+

+

+

+
Saliva

Saliva assay
(658-205)

+

-

U6b-

U6b-

U6b-

Vaginal Secretions
VagSec assay
(124a-372)

+

+

+

+

+

-

*2 year sample tested for blood, 18 month sample for all other body fluids
OC = outside, covered (heat, light, humidity); OUC = outside, uncovered (heat, light, humidity, rain); NA = not available
(+) = body fluid correctly identified; (-) body fluid not detected; U6b(-) = U6b value not acceptable, no further analysis performed
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Table 12. Allele Recovery from Micro-Dissected Sperm Cells Using Various
Amplification Cycles
# of Cells

36 cycles
50 RFU

100 RFU

32 cycles
150 RFU

50 RFU

100 RFU

28 cycles
150 RFU

1
11
11
10
2
2
1
5
19
19
19
16(3) 16(2)
9(1)
10
20(2) 20(2)
20(2) 17(3) 14(3)
10
20
20(2) 20(3)
20(3)
20
16
14
30
20(4) 20(4)
20(3) 2(2)
1(1)
1(1)
40
20(7) 20(7)
20(7) 16(1) 11(1)
11
50
19
19
19
20(1) 19(1) 18(1)
60
20(2) 19(1)
18(1)
20
20
20
70
20(2) 20(2)
20(2)
18
13
12
80
20(1) 20(1)
20(1)
20
20
20
90
20
20
20
20(1) 20(1) 20(1)
100
19(1) 18(1)
18(1)
20
18
16
0
3(1)
3(1)
3(1)
1(1)
0
0
9947a
20
20
20
20
20
20
Blank
0
0
0
0
0
0
(#) = allelic drop-in (not originating from the donor in the study)
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50 RFU

100 RFU

150 RFU

1
3
0
6
12
18
10(1)
10
20
18
15
20
0
20
0

0
0
0
1
3
11
6
2
20
14
6
16
0
20
0

0
0
0
0
2
9
3
0
15
6
1
9
0
20
0

Table 13. Allele Recovery from Sperm Cells Isolated from a Sperm-Sperm (1:1)
Mixture
# Cells

5
20
30
40
60
80
100
0
9947a
Blank

# Alleles Recovered
(out of 14)
50 RFU
Male 1
Male 2
16
15
8
19
20
20
20
20
19
20
20
20
20
20
2
20
20
0

# Alleles Recovered
(out of 14)
100 RFU
Male 1
Male 2
14
15
8
17
20
19
20
20
19
20
20
20
20
20
2
0
20
0
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# Alleles Recovered (out
of 14)
150 RFU
Male 1
Male 2
13
15
8
17
20
19
20
20
19
20
20
20
20
20
2
0
20
0

Table 14. Allele Recovery from Epithelial Cells Isolated from a 1:1 Buccal-Vaginal
Epithelial Cell Mixture
# Cells

5
10
10
10
20
30
0
9947a
Blank

# Alleles Recovered
(out of 14)
50 RFU
Male
Female
7
14
13
14
8
14
14
14
14
14
14
14
0
5
14
0

# Alleles Recovered
(out of 14)
100 RFU
Male
Female
6
12
13
14
8
14
14
14
14
14
14
14
0
5
14
0
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# Alleles Recovered (out
of 14)
150 RFU
Male
Female
6
12
13
14
8
14
14
14
14
14
14
14
0
5
14
0
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